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Introduction 
Worldwide, the total number of miscarriages is estimated at more than 10 million yearly.[1] 
In the Netherlands, approximately 20,000 women annually have a miscarriage, of which 
approximately 50% will undergo medical or surgical treatment in order to remove the 
products of failed conception from the uterine cavity.[2] The incidence of early pregnancy 
failure (EPF) increases with age and, because of rising childbearing age in the Western 
world, EPF management will become of increasing importance.[3]
In today’s era, health care demands preferably cost-effective and non-invasive over costly 
and invasive treatment options whenever possible, with more specifically high treatment 
efficacy, minimal side effects and short treatment duration. Also, during pre-treatment 
consultation, modern patient counseling calls for “shared decision making” on the basis of 
thorough informed consent about the pros and cons of different treatment options, i.e. 
patient preferences.
This thesis focuses on non-invasive medical treatment options in EPF: prostaglandin (miso- 
prostol) treatment with or without pre-treatment of a progesterone receptor blocker (mife- 
pristone).
Early pregnancy failure
EPF is a non-vital pregnancy in the first trimester, defined by the World Health Organization 
as a pregnancy between 6 and 12 to 14 weeks postmenstrual.[4] Other widely used terms 
for EPF are miscarriage, missed abortion or spontaneous abortion, not to be confused 
with medical abortion which implicates the intended termination of a vital pregnancy in 
the first trimester.  
Nowadays, the diagnosis of EPF is usually made by ultrasound examination showing an intra- 
uterine gestational sac with fetal parts and no cardiac activity or an “empty” gestational 
sac without embryonic pole (figure 1). Studies examining cut-off values for gestational sac 
diameter and embryo size, state that EPF can only be considered in case of an empty 
gestational sac with a mean diameter of ≥ 25mm, a missing yolk sac with a gestational sac 
diameter of ≥ 20 mm or a crown-rump length ≥ 7mm without cardiac activity.[5, 6] These 
cut-off values may be higher than one would expect based on clinical experience since 
there is inter-observer variability in measurements of sac diameter and crown-rump 
length.[7] If there is any doubt about the accuracy of the diagnosis on EPF or early vital 
pregnancy, for both healthcare professional and patient, a second ultrasound scan should 
be performed at least one week later to ensure a correct diagnosis. 
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Epidemiology and pathophysiology
EPF (6-14 weeks) is a complication in 10-15% of all pregnancies; worldwide more than 20 
million cases of EPF will occur. In the Netherlands, approximately 10,000 women per year 
visit a hospital because of EPF.[3, 9] The real incidence may be even higher, as not every 
case of EPF is being recognized clinically.[10] In more than 50% of the cases embryonic 
factors, mostly numerical chromosomal abnormalities, appear to be the cause of EPF.[11] 
The majority of chromosomal abnormalities (translocations) arise “de novo”. Therefore in 
the Netherlands, in the search for an explanation of recurrent miscarriages, couples are 
eligible for chromosome analysis after two miscarriages.[11-13] In miscarriages after 12 weeks 
of gestation it is more likely that maternal factors play a role such as thrombophilia or 
other diseases.[11, 14-16] 
Age is the most important risk factor for the occurrence of EPF (figure 2). The chance of EPF 
increases with age: 9% for women between 20-24 years, 20% at the age of 35-40 until 40% 
for women older than 40 years.[17] For women older than 45 years the risk may increase to 
75%.[18]
Treatment options in EPF
Guidelines
There is a Dutch guideline for general practitioners and midwives, which provides recom-
mendations for diagnosis and management in case of vaginal blood loss and / or abdominal 
pain up to 16 weeks of gestation. Unfortunately, there is no national guideline concerning 
Figure 1  Embryo (a) and empty gestational sac (b) [8]
a b
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the treatment options for women with EPF.[3] The “Nederlandse Vereniging voor Obstetrie 
& Gynaecologie” (NVOG) has drafted a guideline for the termination of pregnancy before 
24 weeks of gestation, however, it only includes termination of vital pregnancies.[16]
Worldwide, there are several guidelines describing the management options in case of 
EPF: expectant, medical or surgical management. The Royal College of Obstetricians and 
Gynecologists (RCOG) as well as the American College of Obstetricians and Gynecologists 
(ACOG), recommend medical methods (misoprostol) as a safe, effective and acceptable 
alternative to surgical treatment (evidence level A).[20, 21] 
Due to the absence of a Dutch national guideline, there is a large practice variation 
between Dutch hospitals concerning the management of women with EPF. Despite the 
fact that for gynecologists the awareness of the availability to prescribe misoprostol 
doubled between 2005 and 2014, 23 different treatment regimens (including misoprostol 
alone) were used. Even without a national guideline, one third of the Dutch hospitals 
prescribed the combination of mifepristone and misoprostol in case of EPF.[22] 
Expectant management 
Spontaneous miscarriage i.e. expulsion of products of conception usually occur outside a 
clinical setting. It usually starts with little vaginal blood loss or spotting followed by several 
hours of heavy vaginal bleeding. At the same time, women experience an uncomfortable 
and intense pelvic cramping leading to expulsion of tissue. After the passage of pregnancy 
tissue, the bleeding and pain decreases (figure 3). Some patients may also experience 
nausea or vomiting. Complete miscarriage refers to cases in which the products of 
conception are expulsed entirely out of the uterus, after which the cervix is usually closed 
and the uterus is well contracted; vaginal bleeding and pain may only be mild or may have 
resolved.[23]
Figure 2  Miscarriage rates as a function of maternal age [19]
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By expectant management, spontaneous complete evacuation rates of the products of 
conception vary between 30-50% after one week and up to 60-75% after 6 weeks.[25-30] 
Therefore, expectant management is an option for women with EPF despite the risk of 
unplanned (or additional) surgical treatment, prolonged bleeding and/or the need for 
blood transfusion compared to immediate surgical treatment. At the same time, the risk 
of infection and psychological problems appear similar between expectant and surgical 
management.[31] 
If there are no medical reasons to start immediate medical or surgical treatment, like heavy 
bleeding or intra-uterine infection, expectant management for at least one week should 
be advised. Given the high chance of spontaneous expulsion and the risk of complications 
due to interventions, expectant management and “watchful waiting” for at least one 
week, should definitely be discussed with women in case of EPF, which is standard 
procedure in the Netherlands.[3]
Curettage
Curettage was first described in 1950 and has been the preferred treatment option 
worldwide in the following years.[10, 32] Curettage mostly involves mechanical dilatation 
of the cervix and removal of the products of conception using a curette or suction cannula 
(dilatation and curettage, D&C) under general or regional local anesthesia. Nowadays, the 
most common form of suction curettage is called vacuum aspiration (figure 4). A blunt 
curette can be used afterwards to ensure the uterus is completely evacuated. This 
procedure can be performed under local (spinal or pudendal nerve block) or general 
anesthesia.[33] 
Although having an effectiveness of 95-100%, curettage is accompanied by the risk of 
complications such as infections, uterine perforation and incomplete abortion (table 1). 
The incidence of such complications varies in the literature between 0,01% and 1,6%.[31, 
35-37] Recent studies also reveal a high prevalence of intrauterine adhesions (Asherman 
syndrome), potentially interfering with subsequent child wish. Moreover, a higher risk of 
Figure 3  Spontaneous miscarriage [24]
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premature delivery in future pregnancies has been reported. Mechanical dilatation of the 
cervix by force may lead to permanent cervical injury and cervical insufficiency.[38-40] 
Medical treatment with misoprostol
Misoprostol, a synthetic prostaglandin E1 (PGE1, figure 5), was developed in 1973 to 
prevent and treat stomach ulcers. The first publication about sensitivity of the human 
pregnant uterus to prostaglandin analogues dates from 1987.[41] Misoprostol causes 
uterine contractions and softening and ripening of the cervix and may be used to achieve 
partial or complete expulsion of the products of conception or for the prevention and 
treatment of post-partum hemorrhage.[42, 43]
Figure 4  Vacuum aspiration/curettage [34]
Table 1  Curettage and its risk of complications [31, 35-37, 39, 40]
Incidence, %
Uterine perforation 1.01 – 1.0
Excessive bleeding 1.5
Infection 2.6 – 3.5
Additional surgery 4
Cervical lesion 1.0
Intrauterine adhesions (severe) 19.1 (13.7)
Premature delivery in subsequent pregnancy 9.4
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In 1992, el-Rafaey first described the use of medical methods, including misoprostol, for 
uterine evacuation in case of non-vital pregnancies.[46] The prostaglandin E1 analogue 
misoprostol has since then been used worldwide in case of EPF.[10] 
Misoprostol (400-800µg/day) is approved and registered for the prophylaxis of NSAID- 
induced gastric ulcers and for the healing of duodenal and gastric ulcer. As mentioned 
before, due to uterotonic properties leading to myometrial contractions and ripening and 
dilatation of the cervix, it is also used for obstetric and gynecologic indications.[42] Despite 
the proven effectiveness, it has never been officially registered for these indications.[4, 47] 
The prescription of misoprostol in case of EPF is therefore called “off-label use”: the use of 
pharmaceutical drugs for an unapproved indication or in an unapproved age group, 
dosage, or route of administration. Off-label use, after obtaining informed consent of the 
patient, is legal unless it violates ethical guidelines or safety regulations. The off-label 
prescription is generally based on scientific research or guidelines and widely accepted to 
provide patients the most optimal treatment regimen.[41, 43]
Due to low costs (in the Netherlands 1.02 euro for one tablet) and stability at room 
temperature, it may also be an attractive treatment option in low-resource countries.[48] 
It has few systemic side effects, which are seldom severe and self-limiting (table 2).[42] 
Misoprostol can be swallowed orally, placed vaginally or sublingually.[49]  
Different effective treatment regimens have been advocated which showed wide ranges 
of success rates due to different inclusion criteria, routes of administration dosage and 
success criteria. The International Federation of Gynecology and Obstetrics (FIGO) recommends 
the prescription of two doses misoprostol 800µg administered vaginally (three hours 
apart) or two doses misoprostol 600µg sublingual (three hours apart).[10, 49] However, 
a decline in serious infection rate has been reported in case of medical abortion after 
changing the regime of vaginal to buccal administration.[50] In case of EPF, a Cochrane 
Figure 5   Misoprostol, prostaglandin E1; (a) 200 microgram tablet,  
(b) chemical structure [44, 45]
a b
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review described a study comparing 800μg oral with the same dose of vaginal misoprostol 
with no difference in efficacy, although the mean time to expulsion was significantly longer 
in the oral group.[10] At the same time several clinical studies comparing oral and vaginal 
misoprostol have found increased patient satisfaction with the oral route.[51]
In contrast to other Western world countries, in the Netherlands medical treatment starts after 
minimally one week of expectant management.[3] One week of expectant management 
will lead to a spontaneous complete miscarriage in approximately 50%.[25, 32] Unfortunately, 
misoprostol treatment after minimal one week of expectant management, may lead in 
only 50-60% of the cases to complete miscarriage (endometrial thickness < 15mm on 
ultra sonography). Thus, after two weeks, half of the women treated with misoprostol 
alone still have to undergo D&C and may still be exposed to the risks of complications 
associated with surgery.[32] Therefore, a more effective, non-invasive, alternative to miso- 
prostol is wanted.
Medical treatment with mifepristone
Mifepristone, also known as RU-486, was developed in France in 1980 and approved for 
medical abortion in 1987.[52] In response to anti-abortion protests the distribution of 
mifepristone was stopped one month later. However, the French minister of Health 
ordered to distribute mifepristone in the interests of public health: “I could not permit the 
abortion debate to deprive women of a product that represents medical progress.” In 
France, mifepristone was first distributed free of charge for 34.000 women and since 
February 1990 Mifegyne (mifepristone) was sold to hospitals.[53] Although approval in 
other European countries followed quickly, it took until 2000 before mifepristone was 
approved as an oral medical abortion agent in the USA.[54] 
Table 2  Misoprostol, side effects [42]
Incidence, %
Diarrhea > 10
Nausea, vomiting, abdominal pain, headache 1 – 10 
Fever 0.1 – 1 
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Mifepristone is a synthetic steroid, binding tightly to the progesterone receptor leading to 
degeneration of the uterine lining (decidua) and softening of the cervix (figure 6). In vital 
pregnancies it causes detachment of the blastocyst, which leads to decreased production 
of the hormone hCG: human chorionic gonadotropin (hCG inhibits the disintegration of 
the corpus luteum, which produces progesterone). Decreased progesterone production 
results in further breakdown of the decidua. Furthermore, prostaglandin levels are increased 
and the sensitivity of the uterus towards prostaglandins is enhanced leading to uterine 
contractions that may cause expulsion of the detached blastocyst (figure 7). Mifepristone 
is absorbed rapidly (tmax 1-2 hours) and has a long half-live of 26-48 hours.[52, 55, 56] 
A highly effective combination for medical abortion of mifepristone and a prostaglandin 
analogue (gemeprost) was first reported in 1986.[58] The effect of the administration of 
mifepristone and oral PGE1 (misoprostol) on uterine contractions in a double blinded, 
randomized, controlled efficacy trial was described in 1989 by Swahn et al.[59] Since then, 
the sequential combination of mifepristone with misoprostol (M&M) has been shown 
superior to the use of misoprostol alone for four indications: medical termination of vital 
Figure 6  Mifepristone, chemical structure [15]
Figure 7  Mifepristone, mechanisms of action [57]
I detachment of embryo, decrease of hCG, luteolysis. 
II contraction of myometrium.  
III softening and dilatation of cervix.
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pregnancy (abortion) up tot 63 days of gestation, termination of vital pregnancy beyond 
first trimester, preparation for surgical abortion in the first trimester and labor induction in 
fetal death in utero in the second and third trimester (table 3).[4, 60-62] 
In case of termination of a vital pregnancy in the first trimester, the World Health Organization 
advises mifepristone 200mg in combination with misoprostol starting 36-48 hours later. 
Up to 9 weeks of gestation a single dose misoprostol 800μg can be administered vaginal, 
buccal or sublingual or 400μg oral. Between 9 and 12 weeks up to 5 doses misoprostol 
(every 3 hours) can be administered, starting with one dose of 800μg vaginal, then 400μg 
vaginal or sublingual.[4] An explanation for the prescription of low dose mifepristone 
(200mg) is not described in the guideline; one could imagine it’s because of the high costs 
of mifepristone in the context of low-income countries. However, two phase 2 trials showed 
that 600mg mifepristone is superior to the 200mg dose in terms of complete abortion in 
case of medical abortion of vital pregnancies (89% versus 63%).[63, 64] And since the patent 
on mifepristone has expired, the costs are decreasing drastically.[60, 65] Given the current 
evidence-based indications for mifepristone, it appears reasonable to assume that also for 
EPF, misoprostol with pre-treatment of mifepristone may lead to superior treatment results 
compared to misoprostol alone.
Defining successful treatment & follow-up after medical treatment
With regards to the follow-up of women receiving medical treatment: ultrasonography 
seems to be of limited value in predicting the presence of intrauterine remnants one week 
after medical treatment. Previous studies do not provide any clear evidence which endometrial 
thickness corresponds best to the presence of intrauterine pregnancy remnants.[66] 
A study by Rulin et al concludes that a maximum anterior-posterior diameter of 15 mm or 
less, genuine retained products are less likely to be confirmed histologically.[67] Also a 
recent study by Lavecchia et al also reported that a cavity anterior posterior distance of 
Table 3  Indications mifepristone [4, 60-62]
Recommended dose, mg Success rate, %
Preparation for surgical abortion 200 -
Medical abortion first trimester 600 92.5 – 98.7 
Termination of vital pregnancy 
beyond first trimester
600 99
Labor induction, fetal death in utero 
second/third trimester
600 95 – 99 
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more than 15mm was associated with the need for D&C and an unplanned return to the 
emergency department.[68] Another study by Creinin showed a wide range of endometrial 
thickness (1-31mm) two weeks after expulsion of the gestational sac and that endometrial 
thickness generally decreasing with time. These authors suggest that only clinical signs 
and symptoms should guide treatment decisions after medical treatment.[69]
Concerning the follow-up after medical treatment for EPF, the recent Dutch “MisoREST” 
study investigated whether curettage is more effective than expectant management in 
case of an incomplete evacuation after misoprostol treatment. In a randomized controlled trial, 
curettage was more successful than expectant management: 97% versus 76%. Successful 
treatment was defined as a maximum diameter of any contents of the uterine cavity less 
than 10 millimeters six weeks after study entry. The risk of complications was comparable 
between both groups. Only one third of the calculated sample size of patients was 
included because the trial was stopped prematurely due to strong patient preferences for 
expectant management.[66] At the same time, a cohort study by the same research group 
included 203 women who were treated according to their treatment preference. The same 
results were shown compared to the randomized trial: a significant difference in efficacy 
between curettage and expectant management (95% versus 85%) and no difference in 
complication rates.[70] Because expectant management was effective in approximately 
80%, the authors advise that expectant management should be considered first line 
treatment in women with a suspected incomplete evacuation after medical treatment. 
Patient preferences
When considering any treatment, woman’s preferences are important and should be 
included in the decision-making process. If it’s a physician intention to achieve complete 
evacuation without any invasive methods, possibly leading to a time consuming 
treatment, than that may be in conflict with the patient’s wish to get pregnant again as 
soon as possible. For women, pain-related factors and ‘‘time’’ of the treatment process 
(time to achieve complete miscarriage) are most important.[71] The decision making 
process is also influenced by acceptance of pregnancy loss (desire for closure), timing and 
control of the process (home or clinical-based, length of treatment), home and work re-
sponsibilities, pain and physical aversions, prior experiences with spontaneous or medical 
abortion, health and safety of the procedures and opinions of their physician, family and 
friends.[72-74] Additionally, the number of days of bleeding, the overall safety and risk of 
complications are weighed. Nevertheless, the physician’s recommendation is still crucial 
in the decision-making process.[71] 
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Preferences in case of early pregnancy failure
Concerning medical treatment with mifepristone and misoprostol in case of EPF, only one 
trial was found. This study concluded that 88% of women were satisfied with the received 
medical treatment and 70% would choose this same method again if necessary.[75] 
However, in EPF, several studies about the acceptability and quality of life in case of 
medical treatment with misoprostol alone are performed. Women deliberately choosing 
medical treatment are satisfied with their treatment in approximately 70-75%.[76, 77] In 
randomized trials comparing medical versus surgical treatment, women receiving medical 
treatment reported more pain. All other dimensions of the quality of life questionnaire 
and acceptability were not significant different, there were also no significant differences 
between successful or failed medical treatment.[78] However, another study showed that 
women who received surgical treatment after failed medical treatment were less satisfied 
compared to women directly randomized to surgical treatment.[79]
A Dutch study by Graziosi reported that women may be willing to accept some disadvantages 
of medical treatment to avoid curettage; treatment inconvenience may be accepted 
as long as the complete evacuation rate is high.[80] Women prefer medical treatment as long as 
the success rate exceeds 65% and approximately 85% of women would prefer medical 
treatment if its complete evacuation rate would reach 80% (figure 8).[81]  
Figure 8  Women’s preferences for misoprostol relative to curettage [81]
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Besides effectiveness, also complication rate and days of bleeding influences patient 
treatment preference. Another Dutch study by Wieringa showed that by decreasing the 
complication rate of expectant management the percentage of women preferring curettage 
declined from 58% to 35% in case of a difference in complication rate of 8%.[74]
Cost-effectiveness
Several studies conclude that effective medical treatment options for EPF may be less 
expensive than surgical treatment.[36, 82-84] Direct costs per case appear significantly 
lower but indirect costs may be equal for both groups.[85] By increasing the complete 
evacuation rates of the medical treatment, by adding mifepristone, the total direct costs 
per patient may be reduced compared to the curettage group. Since the costs of 
mifepristone will drop drastically as the patent has expired, even more cost reduction can 
be expected. At the same time, women will not be exposed to surgery and its risk of 
complication on short- and long-term. However, healthcare costs are not only dependent 
on guidelines or protocols, but are also determined by the preferences of the patient. 
When a woman prefers medical treatment and the desire to avoid surgery is high, medical 
therapy becomes less costly and even more efficacious.[81, 83]
Thesis 
In this thesis, several medical treatment options in EPF are analyzed, which may lead to 
higher complete evacuation rates: the combination of mifepristone with misoprostol 
versus misoprostol alone. By demonstrating the effectiveness of this combination, it may 
be possible to
• offer women with a miscarriage an effective alternative to surgery
• increase patient satisfaction 
• limit the number of hospital admissions
• reduce the number of short- and long-term complications
• prevent overtreatment and thereby increase the quality of health care
• realize cost savings for healthcare services
• create a promising therapy for low-resource countries
21
INTRODUCTION
1
Aims of this thesis
• To review the available literature on the added value of mifepristone to current 
non-surgical treatment regimens in women with EPF (chapter 2).
• To compare the success rates of sequential use of mifepristone and misoprostol versus 
misoprostol alone in a single center retrospective cohort study (chapter 3). 
• To analyze the current use in the Netherlands of medical treatment in early pregnancy 
failure and estimate the willingness to prescribe mifepristone in the future depending 
on effectiveness and costs: a nationwide questionnaire (chapter 4).
• To investigate the effectiveness and health-related quality of life of the sequential 
combination of mifepristone with misoprostol versus the use of misoprostol alone in 
terms of complete evacuation of the products of conception from the uterus, a pilot 
study (chapter 5).
• To compose a research protocol of a sufficiently powered, multi-center, randomized, 
double blinded and placebo-controlled trial to test whether, in EPF, the sequential 
combination of mifepristone with misoprostol is superior to misoprostol only (chapter 6).
22
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Abstract
Objectives 
Early pregnancy failure (EPF) is a common complication of pregnancy. Surgical intervention 
carries a risk of complications and, therefore, medical treatment appears to be a safe alternative. 
Unfortunately, the current medical treatment with misoprostol alone has complete evacuation 
rates between 53% and 87%. Some reports suggest that sequential treatment with mife- 
pristone and misoprostol leads to higher success rates than misoprostol alone.
Study design
To evaluate the added value of mifepristone to current non-surgical treatment regimens 
in women with EPF we performed a systematic literature search. Electronic databases were 
searched: PubMed, Cochrane Library, Current Controlled Trials, and ClinicalTrials.gov. Clinical 
studies, both randomized and non-randomized trials, reporting on the added value of mife- 
pristone to current nonsurgical treatment regimens in women with EPF were included. 
Data of sixteen studies were extracted using a data extraction sheet (based on the Cochrane 
Consumers and Communication Review Group’s data extraction template). The methodo- 
logical quality was assessed using the Cochrane Collaboration Risk of Bias tool.
Results
In five randomized and eleven non-randomized trials, success rates of sequential treatment 
with mifepristone and misoprostol in case of EPF varied between 52% and 95%. Large 
heterogeneity existed in treatment regimens and comparators between studies.
Conclusions
The existing evidence is insufficient to draw firm conclusions about the added value of 
mifepristone to misoprostol alone. A sufficiently powered randomized, double blinded 
placebo-controlled trial is urgently required to test whether, in EPF, the sequential combination 
of mifepristone with misoprostol is superior to misoprostol only.
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Introduction
Early pregnancy failure (EPF) is a common complication of pregnancy, as approximately 
15% of all clinical pregnancies will end in a non-viable pregnancy (6–14 weeks). The real 
incidence might be even higher, as not every case of EPF is being recognized clinically. 
The incidence increases with age and because of rising childbearing age in the Western 
world, EPF will become of increasing importance. If expectant management does not 
lead to spontaneous miscarriage, a surgical or medical treatment may be chosen in order 
to remove the products of conception from the uterus.[1-4]
For many years, surgical evacuation has been the preferred option for treating EPF, as it is 
associated with complete evacuation rates of 93–98%.[5-7] However, surgical evacuation 
is associated with high costs and carries a small risk of complications such as pelvic 
infection, cervical injury, uterine perforation, excessive bleeding, and cervical insufficiency 
in following pregnancies. The incidence of such complications varies in the literature 
between 0,01% and 1,2%.[8-10] Worrying may also be the findings reported by a recent 
systematic review revealing a high prevalence of intrauterine adhesions (19,1%) after 
surgical evacuation, potentially interfering with subsequent child wish.[11]
An alternative to surgical evacuation is therefore worth considering. In EPF, expectant 
management for at least one week is a reasonable and successful approach leading to a 
spontaneous complete evacuation in around 50% of woman.[12] There are no serious 
medical risks associated with this watchful waiting strategy.[12]
In first trimester termination of a viable pregnancy, medical methods are proven effective, 
safe and described by patients as a natural and highly acceptable method.[13-19] Medical 
treatment for EPF using the prostaglandin E1 analogue misoprostol was first described in 
1992 by El-Refaey.[20] Complete evacuation rates after two doses of misoprostol vary 
between 53% and 87%. This variation may be explained by differences in the duration of 
expectant management before medical treatment was started.[3, 5, 21]
Complete evacuation rates after medical treatment might be improved by adding mife- 
pristone to misoprostol.[5, 21] Mifepristone, a synthetic steroid, is a competitive progesterone 
receptor antagonist and a glucocorticoid receptor antagonist. Mifepristone is licensed for 
four indications, including medical termination of a viable pregnancy up to 63 days of 
gestation leading to complete evacuation rates of 95%.[22, 23] The sequential combination 
has also already been shown superior to the use of misoprostol alone for labor induction 
in case of fetal death in the second and third trimester.[24, 25] Therefore it might be that 
also for EPF, mifepristone with misoprostol is more effective than misoprostol alone.
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The aim of the present study was to systematically review whether addition of mifepristone 
to current non-surgical treatment regimens in women with EPF is beneficial.
Materials and methods
We reviewed the available literature on the added value of mifepristone to current non- 
surgical treatment regimens in women with EPF. EPF was defined as either an anembryonic 
gestation with a blighted ovum or as an early embryonic/fetal demise showing an embryo 
without cardiac activity. Two reviewers systematically searched the literature from 1983 
(first use of mifepristone by WHO) to May 2015 to retrieve all trials, randomized or non-
randomized, reporting data on the use of mifepristone in non-surgical treatment regimens 
for EPF. PubMed and Cochrane Library electronic databases were searched and reference 
lists were scanned. Databases of current clinical trials were checked: Current Controlled 
Trials (http://controlled-trials.com/) and ClinicalTrials.gov (http://clinicaltrials.gov/).
The following Mesh terms or keywords were used to search all trial registers and databases: 
(Abortion, spontaneous OR Abortion, missed OR Miscarriage OR Pregnancy failure) AND 
mifepristone AND misoprostol AND humans.
Two reviewers performed eligibility assessment independently. Methods of the analysis 
and inclusion criteria were specified and documented in advance. Disagreements between 
reviewers were resolved by consensus. All clinical studies, both randomized and non- 
randomized trials, reporting on the added value of mifepristone to non-surgical treatment 
regimens in women in case of EPF were included. Reviews, case reports and studies for 
which no full text was available were excluded. Studies including vital pregnancies, 
pregnant women in second or third trimester or including only incomplete miscarriages 
were also excluded. Articles were first checked for eligibility and relevance by screening 
title and abstract and second by examining the full text of potentially relevant studies.
A data extraction sheet (based on the Cochrane Consumers and Communication Review 
Group’s data extraction template) was developed. Items assessed included design, participants, 
treatment, (assessment of) primary and secondary outcomes, follow-up and complications. 
The methodological quality of the included studies was assessed using the Cochrane 
Collaboration Risk of Bias tool.
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Results
The search resulted in 154 articles (figure 1). One Cochrane review was available describing 
two trials using mifepristone treatment for EPF.[3] These trials were already found in the 
PubMed search. A search of the Cochrane Library did not yield any additional useful 
articles. In the clinical trials register (www.clinicaltrials.gov) one randomized, double 
blinded placebo-controlled trial was found.
Thus, a total of 155 articles were found, of which 139 were excluded for reasons mentioned 
in figure 1. In total, sixteen articles were included in our analysis consisting of five randomized 
controlled trials and eleven non-randomized trials. Meta-analysis could not be performed 
due to the heterogeneity in treatment protocols.
Figure 1  Flowchart
Literature search (n=155)
Databases:
- Pubmed
- The Cochrane Library
- Current Controlled Trials
- ClinicalTrials.gov 
Excluded (n=139)
- Medical abortion
- Second/third trimester
- Not a clinical trial
- Other   
Articles screened on basis of title and abstract 
Included (n=16)
Randomized trials (n=5) Non-randomized trials (n=11) 
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Randomized controlled trials, non-blinded
Five randomized controlled trials using mifepristone with misoprostol as a treatment for 
EPF were analyzed (tables 1 and 2). In general, the methodological quality of included 
studies was mediocre at best as illustrated per study in figure 2.
Figure 2  Overview of methodological quality of reporting of included RCT studies
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The first randomized controlled trial performed by Nielsen et al. in 1999 included both 
women with EPF and incomplete miscarriages. Nielsen et al. compared sequential mife- 
pristone and oral misoprostol treatment with expectant management reporting complete 
evacuation rates of 82% versus 76%.[26]
The studies performed by Stockheim et al. and Kushwah et al. included only women with 
EPF. The treatment regimen in the study of Stockheim et al. consisted in the intervention 
group of mifepristone 600µg followed by one dose of oral misoprostol 800µg, and was 
successful in 65,5%. The control group received no mifepristone but two doses of oral 
misoprostol 800µg leading to a complete evacuation rate of 73,6%.[27] Kushwah et al. 
included women with EPF between six and fourteen weeks of gestation. 48 h after receiving 
mifepristone 200mg orally, women were randomized to receive misoprostol sublingually 
or orally. Complete evacuation rates after 22 h of 92% versus 84% were described which 
was not statistically significant.[28]
A fourth study by Torre et al. compared immediate versus delayed medical treatment with 
sequential mifepristone and vaginal misoprostol leading to a statistically significant difference 
in success rates. Immediate treatment was started directly after diagnosis leading to a 
complete evacuation rate of 81%. The delayed treatment regimen was started after one 
week of expectant management. During this week 23% of women experienced a spontaneous 
complete evacuation; delayed medical treatment was successful in 53% of the remaining 
women. Vacuum aspiration in the immediate treatment group was required in 19,1% versus 
43,5% of the women in the delayed treatment group. The rate of emergency vacuum 
aspiration was higher in the sequential treatment arm; however, vacuum aspiration performed 
on patient request was also recorded as an emergency procedure. The rate of vacuum 
aspiration in case of retained products of conception was not significantly different between 
both groups.[29]
In the clinical trials register (www.clinicaltrials.gov) one randomized, double blinded 
placebo -controlled trial was found comparing two combinations of drugs in case of EPF, 
sequential mifepristone with buccal misoprostol versus placebo with buccal misoprostol. 
Seventeen patients were included; combined mifepristone and buccal misoprostol treatment 
led to success rates of 62,5% while success rates of 55,6% were described in the placebo 
group after 24–48 h. One week after randomization complete evacuation rates increased 
to 87,5% and 66,7%. The trial was prematurely terminated because of poor enrolment.[30]
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CHAPTER 2
Non-randomized trials
Eleven non-randomized controlled trials using mifepristone with misoprostol as a treatment 
for EPF were analyzed (table 3). An overview of the methodological quality per study of 
included studies is shown in figure 3. In 1992, El-Refaey was the first to report a prospective 
Figure 3  Overview of methodological quality of reporting of included non-RCT studies
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study on the management of 60 women with EPF with a combination of mifepristone and 
oral misoprostol. Despite the short interval between treatment and determination of the 
outcome (4 h), this treatment regimen appeared successful in 95% of the cases.[20] Five 
years later, Nielsen described a prospective trial including 31 women with EPF receiving 
sequential mifepristone and oral misoprostol treatment. Success rates of 52% were 
reached. Authors concluded that these results do not support the use of mifepristone and 
misoprostol in women wishing the miscarriage to be evacuated quickly.[31] However, 
from 2001 on, nine non-randomized trials were published and these reports demonstrated 
that a medical treatment of sequential mifepristone and misoprostol is effective in 67–93% 
without serious adverse events.
Wagaarachchi et al. described a consecutive series of 220 women with EPF before thirteen 
weeks of gestation. All women had chosen to undergo medical treatment (combined 
mifepristone with vaginal misoprostol) leading to an overall success rate of 84,1%. After 
excluding all women who had surgical evacuation by choice after medical treatment 
was started, the success rate was 86,4%.[32] One year later, Wagaarachchi reported 
another prospective trial using mifepristone in combination with sublingual misoprostol. 
Fifty-six women with EPF were included both with (43,9%) and without (66,1%) symptoms 
of vaginal bleeding or pain. The overall success rate was 83,9%. The medical treatment 
regimen failed in 10,5% of the women having symptoms at presentation compared 
to 18,9% of the women who were asymptomatic (p = 0.704).[33] In 2002, Grønlund et al. 
reported on a prospective trial including 176 women with alternating treatment regimens 
every four months. Patients were randomized to medical treatment with sequential mife- 
pristone and vaginal misoprostol, medical treatment with vaginal misoprostol only or surgical 
evacuation. Concerning medical treatment, no improvement in the expulsion rate by pre- 
treatment with mifepristone was reported (74% versus 71%). Although significantly more 
women needed acute evacuation because of heavy bleeding in the intervention group 
(11% versus 1%, p < 0.05), no patient in either study group needed a blood transfusion.[34]
Coughlin et al. assessed the efficacy of a lower and higher dose of mifepristone in a small, 
prospective study in 103 women. With either drug regime (sequential mifepristone 
200mg or 600mg followed by oral misoprostol) an initial success rate of 66–70% was 
reached. In case of incomplete evacuation ten days after treatment, a further 13–14% raise 
in success rates was achieved after another ten-day period of expectant management or 
a second dose of oral misoprostol. Both drug regimens were well tolerated; there was no 
statistically significant difference in overall success rates between both groups. A significant 
reduction in the amount of bleeding was seen in the 200mg mifepristone group versus 
the 600mg mifepristone group. However, only one patient required emergency evacuation 
because of heavy bleeding; this patient received 200mg mifepristone.[35]
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CHAPTER 2
A pilot study including 30 women all receiving sequential mifepristone and vaginal miso- 
prostol treatment was performed by Schreiber et al. Besides reporting success rates of 
93%, also the acceptability of medical management was studied. The overall experience 
and acceptability of the participants was classified as ‘‘positive’’ (54%) and ‘‘neutral’’ (32%). 
Regarding patient preference, 86% of the women would prefer medical treatment again 
if this would be needed in the future and 89% would recommend medical treatment to 
a friend.[36]
Kollitz et al. published a prospective study including 123 patients with EPF and incomplete 
miscarriage. An overall success rate of 83% using mifepristone and vaginal misoprostol 
(two doses) was achieved; treatment success occurred in 80% after a single dose of 
misoprostol. Adverse outcomes, mostly infection, were observed in only 2% of cases.[37]
Three retrospective studies were retrieved. First, Colleselli et al. included 168 women in a 
retrospective chart review. The treatment consisted of 600mg mifepristone followed by 
oral misoprostol and subsequent administration of vaginal misoprostol every 6 h, with a 
maximum of three doses total. A complete evacuation rate of 61% was reached.[38] 
Second, a retrospective cohort analysis by Greenland et al. described success rates of 88% 
in 207 women receiving mifepristone followed by oral misoprostol in case of EPF before 
twelve weeks of gestation.[39] A third retrospective study on 301 women was recently 
published by our group, comparing sequential mifepristone and vaginal misoprostol 
treatment to vaginal misoprostol alone in women with EPF before fourteen weeks of 
gestation. This study showed complete evacuation rates of 67% versus 54%.[21]
Comment
Main findings
In case of EPF, this systematic review reveals complete evacuation rates with sequential 
treatment with mifepristone and misoprostol of 52–95%. No serious adverse events were 
reported in the included trials.
Strengths and limitations
Our systematic review was the first to evaluate the added value of mifepristone to current 
non-surgical treatment regimens in case of EPF. However, due to the limitations of the 
included studies, firm conclusions cannot be drawn. The studies analyzed may be 
criticized because of small sample size and non-blinded design. Meta-analysis could not 
be performed due to the heterogeneity in treatment protocols; particularly treatment of 
women in the control group was different in each trial.
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Since the definition of EPF is not well defined, inclusion of women in the reported trials 
was based on heterogeneous inclusion criteria. There is no international consensus on the 
definition of EPF; for example, the RCOG and FIGO use a limit of 12 weeks amenorrhea 
whereas the World Health Organization maintains a limit of 14 weeks amenorrhea. Since 
there is also no consensus on the definition of successful treatment, the reported trials 
determined the study outcome at different time points and based on various criteria such as 
an empty uterus seen on ultrasound or whether surgical intervention had been performed.
Interpretation
Expectant management
In all trials reported, the treatment started immediately after diagnosis. However, there are 
no serious medical risks associated with a watchful waiting strategy. Luise followed more 
than 1000 women with EPF for up to four weeks after diagnosis. Successful spontaneous 
miscarriage occurred in 52% of women within fourteen days of inclusion. Complications 
occurred in 1% of expectantly managed patients.[12] In the Netherlands medical or 
surgical treatment is started generally after a minimum of one week of expectant 
management, because of an expected spontaneous complete evacuation rate of around 
50% during this expectant management.[12]
Mifepristone
In some studies a low dose of 200mg mifepristone was used; this may have resulted in 
lower complete evacuation rates.[29, 32] A dose of 600mg mifepristone is advised by the 
manufacturer based on phase 2 trials for medical termination of a viable pregnancy up to 
63 days gestation.[24] These trials revealed that mifepristone 600mg is superior to 
mifepristone 200mg in terms of complete evacuation in case of medical abortion of a 
viable pregnancy: 89% versus 63%.[40, 41] Moreover, there is no difference in side effects 
compared with lower doses of mifepristone.[22, 24, 42] However, Birgerson et al. and the 
World Health Organization Task Force compared low and high doses of mifepristone in 
case of medical termination of a viable pregnancy, and found similar failure rates.[43, 44]
At this moment, the World Health Organization and the ‘‘Dutch Society for Obstetrics and 
Gynecology’’ advises mifepristone 200mg in case of termination of a viable pregnancy in 
the first trimester.[45, 46] Although inferiority of the 200mg dose is reported, this low-dose 
regimen may be probably due to the relatively high costs of mifepristone. In the context 
of low-resource countries, the discrete inferiority is considered to be acceptable. However, 
in order to achieve an optimal effect, based on phase 2 trials, a dose of 600mg mifepristone 
may be preferred in further trials.[40, 41]
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Misoprostol
Regarding misoprostol, it should also be noticed that the optimal regimen, dose and route 
of administration has not yet been established.[3] Different misoprostol regimens in the 
reported studies of this review could have influenced the complete evacuation rates. 
For example, the different misoprostol regimen in the trial of Stockheim et al., 800µg 
once in the intervention group versus 800µg twice in the control group, may explain 
higher success rates in the control group.[27] It has been shown that a higher dose of 
misoprostol increases success rates. Hamoda et al. showed that the mean dose misoprostol 
needed to achieve abortion in case of medical termination of a viable pregnancy was 
1324µg.[47] Another study performed by Tang et al. showed that the mean dose of 
misoprostol needed to achieve abortion was 2460µg.[48]
Successful treatment
In all existing guidelines, there are no recommendations concerning the follow-up of early 
pregnancy failure, also literature is limited.[45, 46, 49] Since the rate of clearance of serum 
hCG is dependent on the initial concentration, this should not be used to define complete 
evacuation.[50] The rate of decline does not guarantee that the evacuation is complete.
[51] Follow-up based on clinical judgment and ultrasonography appears to be justified.
[52] It is unclear which follow-up period is most appropriate. Complete evacuation rates of 
89,7% may be reached seven days after medical treatment with misoprostol.[53] A period 
of one week is common practice in the Netherlands.
Costs
According to Graziosi, 85% of women would prefer medical treatment if its complete 
evacuation rate would reach 80%.[54] If complete evacuation rates could be increased by 
adding mifepristone to misoprostol, the total direct costs per patient can be lowered. 
Since the patent on mifepristone has expired recently, it is expected that also the 
pharmaceutical costs per patient will drop drastically.
Graziosi showed that the use of misoprostol for early pregnancy failure after failed expectant 
management is less costly than curettage. The direct costs per case were significantly 
lower (mean difference € 250; 95% CI 184–316, p < 0.001), indirect costs were equal for both 
groups (mean € 457). Differences in direct costs in favor of misoprostol treatment were large 
for women who had complete evacuation after initial medical treatment (direct costs 
€ 137) as compared to those who needed additional curettage after failed misoprostol 
(direct costs € 788).[55]
Practical and research recommendations
A sufficiently powered prospective, randomized, double blinded and placebo-controlled 
trial on this subject is urgently needed.
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Conclusion
The available evidence shows that medical treatment appears to be a safe alternative to 
surgical evacuation, leading to savings and a reduced number of serious complications. It 
represents an option of a less invasive management and gives women more control, and 
is especially suited for women not wanting hospital admission or surgical procedures or 
for patients in low resource countries. Unfortunately, medical treatment with misoprostol 
alone reaches complete evacuation in only half of the women. Adding mifepristone to 
current non-surgical treatment regimens might increase success rates and thereby reduce 
the number of surgical interventions. However, the evidence from the existing literature is 
insufficient to draw firm conclusions concerning the added value of mifepristone.
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Abstract
Objective
Is treatment of early pregnancy failure (EPF) with sequential use of mifepristone and miso- 
prostol more effective than treatment with misoprostol alone?
Study design
In a retrospective cohort study at the Department of Obstetrics and Gynecology of the 
Radboud University Medical Centre, 301 women with early pregnancy failure receiving 
medical treatment between January 2008 and March 2013 were included. Of these, 199 women 
were pre-treated with 200mg mifepristone (orally) followed by 2 consecutive doses of 
800μg misoprostol (vaginally) and 102 women were treated with 2 consecutive doses of 
800μg misoprostol (vaginally) alone.
Results
Complete expulsion was achieved in 66,8% of the women treated with a sequential 
combination of mifepristone and misoprostol versus 54,9% of the women treated with 
misoprostol alone. The difference in rates of complete expulsion was 11,9% (p < 0.05; 95% 
CI 0.3–23,6%).
Conclusions
Medical treatment of early pregnancy failure with a sequential combination of mifepristone 
and misoprostol was more effective than treatment with misoprostol alone. Our findings 
will have to be confirmed by a large prospective multicenter double blinded-randomized 
trial.
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Introduction
Early pregnancy failure (EPF) is a common complication of pregnancy, as 10% to 20% of all 
clinically recognized pregnancies will end in EPF.[1] For many years surgical evacuation 
was the standard treatment, but more recently medical management has gained a 
substantial role in treatment of EPF. Medical management of EPF with the prostaglandin E1 
analogue misoprostol has been the subject of many studies showing complete expulsion 
rates using between 53% and 87%.[2-5] As evidence is growing that surgical management 
may have major long-term consequences, such as intra-uterine adhesions and increased 
spontaneous preterm birth rates in subsequent pregnancies, the potential of successful 
medical treatment of EPF is of utmost importance.[6, 7]
Mifepristone is an anti-progesterone and anti-glucocorticoid drug and is registered for 
induction of abortion in viable pregnancies up to a gestational age of 63 day.[8] The sequential 
combination of mifepristone (200mg) with misoprostol (800μg) has been shown superior 
to the use of misoprostol alone (800μg) for medical termination of viable pregnancies.[9] 
The rate of complete abortion after treatment with a combination of mifepristone and 
misoprostol is reported to be as high as 95%.[10]
Several studies examined the combination of mifepristone and misoprostol in cases of 
EPF and found it an effective and safe alternative to surgical treatment, with success rates 
ranging between 65,5% and 93%.[11-15] Unfortunately, these studies had limitations 
due to study design, small sample size and heterogeneous inclusion criteria. Therefore, 
conflicting findings about the value of mifepristone need to be resolved by additional 
studies.[3] In preparation for this trial we conducted a retrospective study to compare 
complete expulsion rates with a combination of mifepristone and misoprostol versus 
misoprostol alone in women with early pregnancy failure.
Methods
We performed a single-center retrospective cohort study of women treated in the Radboud 
University Medical Centre between January 2008 and March 2013, to study the effectiveness 
of mifepristone in women treated for early pregnancy failure. Ethics approval was not 
required for this study; this was confirmed by our local medical ethics committee.
Patient selection
Mifepristone (Mifegyne1, Exelgyn France, Nordic Pharma, The Netherlands) is registered 
for induction of abortion in the Netherlands. It is solely available in clinics authorized by 
an explicit jurisdictional approval of the Minister of Health. Therefore a strict registration of 
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distributed mifepristone is used in the outpatient clinic. This registration was used to 
identify women treated with mifepristone between April 2010 and March 2013. The use of 
misoprostol (Cytotec1, Pfizer The Netherlands) for the indication EPF is ‘‘off label’’ and also 
registered. To search for patients potentially not listed in these registrations, electronic 
patient records were searched between January 2008 and March 2010 for variables such 
as absent fetal heartbeat and gestational age less than 14 weeks.
Inclusion criteria for this cohort study were the presence of a non-viable pregnancy before 
14 weeks’ gestation and an indication for medical treatment. A non-viable pregnancy was 
defined either as an anembryonic gestation with a blighted ovum or as early embryonic/
fetal demise showing an embryo without cardiac activity. In The Netherlands, expectant 
management for at least one week after the diagnosis has been established is common 
practice, because spontaneous complete expulsion rates of 50% are to be expected 
during this first week.[16]
Exclusion criteria were imminent miscarriage (products of conception passing through 
the cervical os at presentation at the outpatient department) and incomplete miscarriage, 
which was defined as retained products of conception (endometrial lining >15 mm) after 
expulsion of an intrauterine pregnancy.
Treatment protocols
At our clinic, women with early pregnancy failure are counseled according to a local 
protocol with respect to three options: expectant management, or medical or surgical 
treatment. Before April 2010 medical treatment of EPF consisted solely of administration of 
two consecutive doses of misoprostol 800μg vaginally (time interval of 24 h) without 
mifepristone. Thereafter, medical treatment consisted of 200mg mifepristone orally 
followed by 800μg misoprostol vaginally 36 h later administered at home. When cramps 
or vaginal bleeding do not occur within 24 h after the first dosage of misoprostol, women 
are instructed to use another dosage of 800μg misoprostol vaginally the next day.
Outcome measures
The primary outcome parameter was complete expulsion, defined as asymptomatic 
women after clinical signs of a complete miscarriage, or an empty uterine cavity seen on 
vaginal ultrasound, or an empty uterine cavity seen during hysteroscopy, or a histology 
report after surgical evacuation describing the absence of the products of conception. 
The study outcome was determined at different time points depending on the policy of 
the treating physician. Secondary outcome parameters were the different reasons for 
failure of treatment (no expulsion of products, persistent gestational sac, suspected 
residue, excessive blood loss or suspected infected residue) and factors that could affect 
the rate of complete expulsion like gestational age and parity.
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Statistical analyses
SPSS version 20.0 was used for data analysis. Differences between groups were analyzed 
using Pearson’s chi-square test or Fisher’s exact test for categorical variables. The Mann–
Whitney U test was used for non-normally distributed metric variables. Logistic regression 
analysis was performed to identify factors that were associated with treatment success. 
P values smaller than 0.05 were considered significant.
Results
Baseline characteristics were not significantly different between the treatment groups 
(table 1). A total of 311 women were medically treated for early pregnancy failure at the 
Radboud University Medical Centre in the period between January 2008 and March 2013. 
Ten cases were excluded because there were no exact data on the primary outcome. 
A total of 102 women were treated with misoprostol alone and 199 women were treated 
with the sequential combination of mifepristone and misoprostol.
Table 1  Baseline characteristics
 Misoprostol
(N=102)
Mifepristone 
and misoprostol 
(N=199)
P value
Age (years), mean 
SD 
32,6
4.5
33,0
4.9
0.44
Anembryonic gestation 
Embryonic / fetal demise 
28 (27,5%)
74 (72,5%)
54 (27,1%)
145 (72,9%)
1.00
Gestational age amenorrhea (days), mean
SD
71,8
9.8
74,1
10.1
0.08
Ultrasound gestational age (days), mean
SD
53,0
9.8
52,9
10.2
0.99
Nulliparous 39 (38,2%) 81 (40,7%) 0.62
Previous miscarriage 40 (39,2%) 60 (30,2%) 0.15
Previous elective abortion (APLA) 13 (12,7%) 26 (13,1%) 1.00
Previous caesarean section 6 (5,9%) 27 (13,6%) 0.06
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Complete expulsion (table 2) was achieved in 66,8% of the women treated with a sequential 
combination of mifepristone and misoprostol compared to 54,9% of the women treated 
with misoprostol alone. The difference in rates of complete expulsion was 11,9% (p < 0.05; 
95% CI 0,3%–23,6%). In women diagnosed with an anembryonic gestation (AG) the rate of 
complete miscarriage did not differ significantly between the two treatment groups. 
In women diagnosed with embryonic/fetal demise (EFD) the rate of complete expulsion 
after treatment with a sequential combination of mifepristone and misoprostol was 64,1%, 
compared to 44,1% in women treated with misoprostol alone (p < 0.01, difference 20%, 
95%CI: 5,8%–33,3%).
In 113 women who needed a surgical intervention after medical treatment, two were 
diagnosed with an empty uterine cavity during hysteroscopy. Hysteroscopy was performed 
in women presenting more than six weeks after medical treatment with a suspicion of 
retained products of gestation. In three women treated with dilatation and curettage the 
pathologist reported absence of gestational products.
Table 3 shows indications for surgical management after failed medical treatment. 
Most women were surgically treated due to a suspicion of retained products of gestation. 
In women treated with misoprostol alone 30% of the indications for surgical intervention 
were because of a persistent gestational sac, compared to 9% in the group treated with a 
sequential combination of mifepristone and misoprostol (difference 21%, p < 0.01, 95%CI: 
6,6%–35,5%). Ten women treated with a sequential combination of mifepristone and 
misoprostol had a surgical intervention because of excessive bleeding. Among the patients 
treated with misoprostol alone, one patient needed an intervention due to hemorrhage.
Table 2   Outcome measures of consecutive combination of mifepristone and 
misoprostol versus misoprostol alone
Misoprostol, n/N (%) Mifepristone and 
misoprostol, n/N (%)
P value
Complete expulsion rate (total) 56/102 (54,9) 133/199 (66,8) < 0.05
Complete expulsion rate (AG) 21/28 (75) 40/54 (74,1) 1.00
Complete expulsion rate (EFD) 33/74 (44,6) 93/145 (64,1) < 0.01
AG= Anembryonic gestation, EFD= Embryonic or fetal demise 
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After adjusting for gestational age a non-significant declining rate of complete expulsion 
was observed, as shown in Fig. 1 (p = 0.06). No differences in primary outcome were 
observed after adjusting for the difference between time since last menstrual period 
and ultrasound gestational age, parity, prior miscarriages, prior elective abortions or prior 
dilatation and curettage.
Table 3   Indications for surgical intervention after failed medical treatment
Misoprostol, n/N (%) Mifepristone and  
misoprostol, n/N (%)
P value
Surgical intervention (total) 50/102 (49) 67/199 (33,7) < 0.05
Suspected residua 31/50 (62) 44/67 (65,7) 0.70
Persistent gestational sac 15/50 (30) 6/67 (9) < 0.01
Suspected residua with signs  
of infection
3/50 (6) 5/67 (7,5) 1.00
Hemorrhage 1/50 (2) 10/67 (14,9) < 0.05
Figure 1  Complete expulsion rate
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Comment
Main findings
This retrospective study compared rates of complete expulsion of EPF after medical 
treatment with sequential mifepristone and misoprostol to those after treatment with 
misoprostol alone after at least one week of expectant management. Sequential treatment 
with mifepristone and misoprostol resulted in a 66,8% complete expulsion rate and treatment 
with misoprostol alone resulted in a 54,9% complete expulsion rate. The difference in rates 
of complete expulsion was statistically significant.
Strengths and limitations
EPF is a common complication of pregnancy, and therefore we were able to include a 
large group of women. Our baseline data showed no significant difference between the 
two treatment groups. Diagnosis of early pregnancy failure, therapy counseling and 
patient information was standardized. A uniform treatment protocol was available and 
there was a clear and objective outcome definition.
A limitation of our findings is the retrospective study design. The data were collected 
directly from patient charts, which could be inconclusive or incomplete. The allocation to 
the two treatment groups was caused by a protocol change in April 2010, but a minority 
of women was still treated according to the old protocol after 2010.
Interpretation
Success rates of the use of misoprostol alone vary from 53% to 88%.[2, 5, 14, 17-20] These 
studies are heterogeneous in their definition of complete abortion, duration of follow-up 
period and doses of misoprostol.[11-13, 21, 22] As an example, in the studies of Wagaarachchi 
et al. up to 1600μg misoprostol for two consecutive days was given.[21, 22] Others used 
different frequencies of administration such as two consecutive doses of 800μg 
misoprostol followed by an additional dose after one week if necessary.[20] Regarding 
follow-up, Kollitz and Petersen used an endometrial lining of < 30 mm to diagnose 
complete miscarriage after one week.[5, 12] In essence, there is no consensus on the 
diagnosis of a complete miscarriage. Some clinicians or researchers use clinical symptoms 
like the cessation of vaginal blood loss and cramps. Others use ultrasonographic criteria 
such as the absence of a gestational sac or an endometrial lining of less than 15 or 30 mm. 
Some data show that there is no relationship between increasing endometrial resi-
due-thickness and the need for surgical intervention in women treated with misoprostol 
for early pregnancy failure.[23, 24] In our center, clinicians use a maximum endometrial 
lining of 15 mm with absence of vaginal bleeding to diagnose complete miscarriage one 
week after treatment. This may have led to a lower success rate of treatment compared to 
other studies using less stringent criteria for complete miscarriage. We are eagerly awaiting 
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the results of the Dutch ‘‘MisoREST’’ study, ultimately defining the effectiveness of expectant 
management and curettage in symptom-free women with sonographic evidence of 
incomplete evacuation of a miscarriage after misoprostol treatment.
Graziosi et al. found a success rate of misoprostol after one week of expectant management 
of 53,2%, comparable with 54,9% found in our study. Graziosi concluded that these lower 
success rates might be due to this patient selection after one week of expectant 
management.[2] Indeed, Torre et al. conducted a randomized trial to compare delayed 
treatment with direct medical treatment and concluded that delayed treatment is less 
effective than direct treatment.[25] In women treated with mifepristone and misoprostol 
we found a 66,8% rate of complete expulsion after one week expectant management, 
which is comparable with the percentage success found by several other studies (66–74%). 
[14, 15, 26]
Additional findings
The difference in expulsion rates between the two treatment regimens in women with an 
anembryonic gestation (AG) and women having an early embryonic/fetal demise (EFD) 
have not been described in earlier studies. Wagaarachchi et al. described the two groups 
separately but found no significant difference in treatment success.[21] Kollitz et al. described 
a difference between AG and EFD, showing that women with an AG had a success rate 
of 69% compared to 88% in the group of women with EFD.[12] The data of Zhang et al. 
showed that the success rate of treatment of AG was lower compared to the success rate 
of treatment of women having an EFD.[4]
Practical and research recommendations
Reflecting on cost-effectiveness, it may already be clear that medical treatment delivered 
at an outpatient department, with the intention of spontaneous miscarriage at home, will 
decrease costs substantially compared to clinical surgical treatment. Besides, since the 
patent on mifepristone has expired, the costs of mifepristone are already decreasing 
drastically. Because of the decreasing costs of mifepristone, even a small increase in the 
rate of complete expulsion may lead to a decrease in overall treatment costs.
Based on the results of our study, treatment of early pregnancy failure with the sequential 
combination of mifepristone and misoprostol appears to be more effective than miso- 
prostol alone. A randomized, double blind placebo-controlled trial is urgently needed. 
Such a trial could confirm that treatment with mifepristone and misoprostol may lead to 
higher complete evacuation rates and thus a significant reduction of costs.
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Conclusion
In our retrospective study, treatment of early pregnancy failure with a sequential combination 
of mifepristone and misoprostol was significantly more effective than treatment with 
misoprostol alone. These findings should be confirmed by a multicenter double blinded- 
randomized trial.
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CHAPTER 4
Abstract
Objective
To investigate the current and future addition of mifepristone to misoprostol treatment 
(M&M) in case of early pregnancy failure (EPF). 
Study design
A digital questionnaire was distributed to a representative sample of all Dutch hospitals 
(25/79). Gynecologists with focus on early pregnancy of eight academic hospitals, ten 
teaching hospitals, six non-teaching hospitals and one private practice center were 
approached to fill in the survey. The questionnaire consisted of 25 questions concerning 
current practice in EPF with a focus on the use of mifepristone. 
Results
All 25 questionnaires were returned. In non-teaching centers the presence of a local 
protocol was significantly lower compared to academic and teaching hospitals (p 0.012). 
If a local protocol was present, first choice of treatment was medical in 54,5%. Four 
respondents (16%) always prescribed mifepristone in case of EPF. The most common 
reason not prescribing mifepristone was the lack of sufficient scientific evidence. An average 
increase in success rate of 21,7% was desired to prescribe mifepristone in the future for EPF. 
Completeness of evacuation of products of conception from the uterus was usually 
assessed after one week by ultrasonography combined with clinical signs. The cut-off 
point for total endometrial thickness used to diagnose (in) complete evacuation varied 
from 4 until 15 millimeters. If a complete evacuation was not achieved by the initial medical 
treatment, expectant management was proposed just as often as surgical intervention 
(24%). Follow-up after additional expectant management was usually planned after the 
first menstruation. 
Conclusions
For EPF, there is still a large practice variation in the Netherlands concerning treatment of 
patients. The use of M&M in EPF is not common practice, due to the lack of sufficient 
evidence. Physicians are willing to prescribe pre-treatment with mifepristone before 
misoprostol in the future if proven effective.
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Introduction
Early pregnancy failure (EPF) is a common complication of pregnancy. In the Netherlands, 
approximately 10,000 women per year will undergo some form of treatment, in order to 
remove the products of conception from the uterus.[1] The Dutch guideline for general 
practitioners and midwives advise expectant management for a minimum of one week, 
because this leads to a spontaneous complete evacuation rate of approximately 50%.[2-4] 
Surgical treatment (dilatation and curettage, D&C) is associated with high (>95%) efficacy 
rates, but also with higher cost, short- and long-term risks of complications, and possible 
consequences for following pregnancies.[3, 5-10] Medical treatment for EPF with misoprostol 
(a synthetic prostaglandin E1 analogue) started after one week of expectant management, 
is a less invasive alternative, but results in a lower complete evacuation rate of approximately 
50%.[3, 11, 12] 
A new medical treatment option combines pre-treatment with mifepristone, an anti- 
progesterone and anti-glucocorticoid drug, to misoprostol (M&M) and this combination 
appears more effective.[13, 14] Up until now, mifepristone is licensed in the Netherlands for 
four indications namely medical termination of a vital pregnancy up tot 63 days of gestation, 
termination of vital pregnancy beyond first trimester, preparation for surgical abortion in the 
first trimester, and labor induction in fetal death in utero in the second and third trimester.
[15-18] So, it appears reasonable to consider that, also for EPF (non-vital pregnancy in the first 
trimester), M&M is superior to misoprostol alone.[11, 15] Unfortunately, until now the existing 
evidence is insufficient to draw firm conclusions regarding M&M treatment.[13] 
In the Netherlands, there is no national guideline for gynecologists describing diagnostic, 
treatment and follow up options for EPF. Verschoor et al reporting on a national survey in 
2014 concerning treatment options in the Netherlands showed a large practice variation 
between hospitals. The awareness to prescribe misoprostol doubled between 2005 and 
2014 to nearly 100%. However, up until 2014, 23 different treatment regimens (dosages 
and routes of administration) were used, and in many hospitals even more than one 
treatment regimen existed simultaneously. The aforementioned questionnaire focused 
mainly on the use of misoprostol. Mifepristone was prescribed in approximately 37% of 
the hospitals with no further details mentioned.[19] 
This survey was conducted in the context of preparation of a randomized controlled trial 
to test the hypothesis that M&M is superior to the use of misoprostol alone in case of EPF. 
We investigated the presence of a local protocol, the current prescription of mifepristone, 
and possible future intention to prescribe mifepristone in case of EPF. Since evidence 
based literature regarding follow up and optimal diagnostics defining (un) successful 
treatment after medication is lacking, we also focused on these items.[20, 21] 
66
CHAPTER 4
Materials and methods
An online questionnaire was developed using Google Forms. Twenty-five questions were 
compiled about a local protocol, the current prescription of medical treatment and 
mifepristone, the intention to use M&M in the future, and follow-up procedures (diagnostic 
tools and time period). In the Netherlands, a representative sample of gynecologic centers 
was approached (25/79, 32%) consisting of 8 academic centers, 10 teaching hospitals, 6 
non-teaching hospitals and 1 private practice center. Gynecologists with focus on early 
pregnancy working in these centers were contacted beforehand by telephone and/or 
e-mail and informed about the following questionnaire. Questionnaires were sent 
between February and July 2017. An email once again explained the purpose of the survey 
and the confidentiality, and provided a direct link to the digital questionnaire. One 
reminder was sent out after two weeks. The survey was based on voluntary participation 
and patients were not involved, therefore ethical approval was not necessary. 
Statistical analyses
Data collection was confidential and anonymous. Data were automatically entered into a 
spreadsheet after completion of the questionnaire. Analysis was performed per type of 
hospital (academic versus (non-) teaching hospitals), and between centers with and 
without a local protocol. The private practice center was analyzed as a non-teaching 
hospital. SPSS version 24 was used for data analysis. Differences between groups were 
analyzed using the Pearson’s chi-square test or the Fisher’s exact test for categorical 
variables. P values smaller than .05 were considered significant. 
Results
All twenty-five questionnaires were returned (response 25/25, 100%), two questionnaires 
from non-academic centers were incomplete; they were included in the analysis up to the 
point where they were completed. A local protocol for EPF was present in 88% of all 
responding hospitals, in 100% of academic and teaching hospitals versus 57,1% in 
non-teaching hospitals (p 0.012, table 1). In the remaining 12% of the centers, so-called 
agreements about the preferred treatment method exist, but not documented in a 
protocol. One week of expectant management was not significant different between 
academic or non-academic centers, or hospitals with or without a local protocol. If a local 
protocol was present, the first choice of treatment was medical in 12/22 (54,5%), and 
mifepristone was described in 9/22 (41%). Of non-teaching hospitals with a local protocol, 
3/4 (75%) recommended the prescription of mifepristone compared to 6/18 (33,3%) of 
the academic and teaching hospitals (p 0.125).  
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When analyzing all hospitals, mifepristone was prescribed ‘always’ by 4/25 (16%), ‘usually’ 
by 1/25 (4%), ‘only when indicated’ by 9/25 (36%), and ‘never’ by 9/25 (36%) respondents 
(table 2). The most mentioned reason (26,1%) for not prescribing mifepristone in case of 
EPF was lack of evidence of effectiveness. Although the Dutch drug leaflet of mifepristone 
recommends taking mifepristone in the presence of a physician or one of his/her 
employees, two hospitals followed this advice. The complete evacuation rate after 
mifepristone and misoprostol treatment was estimated between 50% and 100% with 
similar side effects compared to treatment with misoprostol alone. The required average 
increase in success rate for physicians to prescribe mifepristone as part of the standard 
medical treatment in case of EPF was 21,7%.   
The mean time period between medical treatment and first follow-up visit was 1,3 weeks, 
with a median of 1 week (table 3). To determine complete evacuation of the products of 
conception from the uterus, most centers used the combination of clinical signs and ultra-
sonography 16/25 (64%). When ultrasonography was used, whether or not combined 
with clinical signs, complete evacuation was most often based on evaluation of the 
sonographic impression by the physician without any measurements (11/25, 44%). When 
measuring the total endometrial thickness, the used cut-off point for maximum anteri-
Table 1  Local protocol for early pregnancy failure
Type of clinic n/N (%)
Academic Teaching Non-teaching 
Local protocol present?    
Yes 8/8 (100) 10/10 (100) 4/7 (57,1)
No 0 0 3/7 (42,9)
First choice of treatment    
Medical 6/8 (75) 5/10 (50) 1/4 (25)
Patient and/or doctor preference 2/8 (25) 5/10 (50) 3/4 (75)
One week of expectant management 
Always 3/8 (37,5) 3/10 (30) 0
Usually 4/8 (50) 7 (70) 4/7 (57,1)
Only when indicated 1/8 (12,5) 0 3/7 (42,9)
Mifepristone recommended in protocol
Yes 2/8 (25) 4/10 (40) 3/4 (75)
No 6/8 (75) 5/10 (50) 0
Unknown 0 1/10 (10) 1/4 (25)
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or-posterior diameter varied from four up to fifteen millimeters, with a median of ten 
millimeters. If retained products of conception were suspected after medical treatment, 
24% of the centers proposed expectant management, 24% administration of misoprostol, 
and 24% an invasive treatment option (hysteroscopy or curettage). In case of expectant 
management, a second follow-up visit was arranged after the first spontaneous 
menstruation in 15/25 clinics (60%). Other time points used by the remaining centers were 
divergent between two and six weeks or only in case of symptoms. All of the variables 
mentioned above, regarding follow-up and if necessary further treatment, showed no 
Table 2  Use of mifepristone
Type of clinic 
Academic Teaching Non-teaching
Prescription of mifepriston n/N (%)    
Always 0 2/10 (0) 2/7 (28,6)
Usually 1/8 (12,5) 0 0
Only when indicated 3/8 (37,5) 4/10 (40) 2/7 (28,6)
Never 4/8 (50) 3/10 (30) 2/7 (28,6)
Unknown 0 1/10 (10) 1/7 (14,3)
Dosage mifepristone n/N (%)
200mg 1/1 (100) 1/2 (50) 2/2 (100)
600mg 0 1/2 (50) 0
Time interval mifepristone – misoprostol 
Mean (hours) 36 32 30
Range 36 8 – 48 24 – 36
Estimated success rate n/N (%)
0 – 25 % 0 0 0
25 – 50 % 0 0 0
50 – 75 % 0 1 (50) 1 (50)
75 – 100 % 1 (100) 1 (50) 1 (50)
Side effects compared to misoprostol alone n/N (%)
More 1 (100) 0 0
Similar 0 1 (100) 1 (50)
Less 0 0 1 (50)
Required increase rate to prescribe mifepristone
Mean 21,9 18,9 24,2
Range 5 – 35% 10 – 35% 15 – 30%
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significant differences between academic, teaching and non-teaching centers, neither 
when comparing centers with or without a local protocol. 
Table 3  Evaluation of treatment effect
Type of clinic 
Academic Teaching Non-teaching
Time period
Mean (weeks) 1,8 1,1 1,2
Range 1 – 6 1 – 2 1 – 2 
Diagnostic tool n/N (%)
Ultrasonography, no measurements 1/8 (12,5) 2/10 (20) 0
Measurement of ET by ultrasonography 0 1/10 (10) 2/7 (28,6)
Clinical signs 1/8 (12,5) 0
Ultrasonography and clinical signs 6/8 (75) 6/10 (60) 4/7 (57,1)
Unknown 0 1/10 (10) 1/7 (14,3)
Cut-off point ET
Mean (millimeters) 8,8 11,25 8,2
Range 4 – 12 8 – 15 4 – 15 
Treatment in case of retained products of  
conception n/N (%)
Expectant management 4/8 (50) 1/10 (10) 1/7 (14,3)
Misoprostol 1/8 (12,5) 2/10 (20) 3/7 (42,9)
D&C 0 2/10 (20) 1/7 (14,3)
Hysteroscopy 1/8 (12,5) 1/10 (10) 1/7 (14,3)
Patient and/or doctor preference 2/8 (25) 3/10 (30) 0
Unknown 0 1/10 (10) 1/7 (14,3)
Planned follow-up visit n/N (%)
After first menstruation 5/8 (62,5) 7/10 (70) 3/7 (42,9)
Other 2/8 (25) 3/10 (30) 3/7 (42,9)
Unknown 1/8 (12,5) 1/10 (10) 1/7 (14,3)
ET: endometrial thickness
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Comment
Main findings
In our sample of gynecologic centers in the Netherlands (32%), a local protocol was present 
in 88% with a significant difference between academic and teaching (100%) versus 
non-teaching centers (57,1%). The first choice of treatment was medical in 54,5%. Only 20% 
of the respondents always or usually prescribe M&M in case of EPF, estimating the 
complete evacuation rate between 50% and 100% with similar side effects compared to 
treatment with misoprostol alone. The most given reason for not prescribing mifepristone 
for EPF, is lack of sufficient scientific evidence of effectiveness. An average increase in 
success rate of 21,7% is required to prescribe mifepristone in the future for EPF. Treatment 
effect is usually assessed by ultrasonography and clinical signs (64%). The cut-off point 
for total endometrial thickness used to diagnose complete evacuation varies from 4 until 
15 millimeters. If complete evacuation is not achieved by the initial medical treatment, 
expectant management including a second follow-up visit after the first following 
menstruation was proposed just as often as surgical intervention. 
Strengths and Limitations 
All questionnaires sent were returned by a representative sample of all gynecologic 
centers in the Netherlands. The fact that we used a self-constructed survey, may have led 
to common method bias. However, based upon the questions asked, we believe this has 
not influenced the results.
Interpretation
The large practice variation in the Netherlands reported in our survey is comparable to 
earlier results reported by Verschoor et al in 2014.[19] The percentages described in our 
study of academic, teaching and non-teaching hospitals reporting medical methods as 
first treatment option in case of EPF are comparable with their results. Up until now, there 
is national guideline of gynecologists describing the treatment options in case of EPF. 
However, recommendations are made in a Dutch guideline for general practitioners and 
midwives, which advises expectant management for one or two weeks after sonographic 
diagnosis of EPF. At follow-up, ultrasonography will determine (in) complete evacuation 
and whether referral to a gynecologists is necessary.[4] Despite these recommendations, 
only 24% of our respondents (i.e. gynecologists) always follow this advice before starting 
any treatment.[4] Because this guideline is specifically made for general practitioners and 
midwives, it is possible that part of the gynecologists is not aware of the existence of this 
guideline, causing physicians to start treatment immediately after diagnosis. However, this 
guideline advises an expectant management. Further, also patient preferences could also 
have major influence on the time of referral to a gynecologic center. If women do not 
want to wait any longer for spontaneous miscarriage to occur, i.e. because of their wish to 
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get pregnant again as soon as possible or inconvenience of impending expulsion or 
blood loss, this may persuade a physician to start treatment immediately. Also financial 
components in the Dutch reimbursement system may potentially drive physicians to 
start treatment immediately since interventions still yield higher remunerations than an 
expectant policy.[22]
Although previous studies do not provide sufficient evidence about time period and 
diagnostic tool to define success, and since there is no Dutch guideline, it’s interesting to 
notice that assessment of treatment success appears similar in almost every center in the 
Netherlands.[21] Most respondents planned a visit at the outpatient department one 
week after medical treatment. Ultrasonography combined with clinical signs was mostly 
used to determine treatment effect. An average cut-off point of 10mm for endometrial 
thickness to suspect retained products of conception is reported, which in our opinion 
might lead to the unjustified diagnosis of incomplete evacuation. A study by Rulin et al 
conclude already in 1993 that in case of a maximum anterior-posterior diameter of 15 mm 
or less, retained products are less likely to be confirmed histologically.[23] Also a recent 
study by Lavecchia et al demonstrated that in women with a cavity anterior-posterior 
distance of less than 15 mm, 87,1% did not need D&C afterwards.[24] Despite the fact that 
the results by the MisoREST-study have just recently been published, recommending that 
expectant management should be considered first line treatment in women with 
suspected incomplete evacuation after initial medical treatment, already 26% of our 
respondents propose an expectant management until the first following menstruation.
[20] Seventeen of our twenty-five respondents participated in the MisoREST-study of 
which one respondent answered that their follow-up protocol was recently changed 
based on these results.
The amount of hospitals prescribing mifepristone “always” or “usually” in case of EPF is 
lower in our survey compared to the numbers mentioned by Verschoor: 20% versus 38%.
[19] This difference might be due to our selection of hospitals.[13] It is interesting that all 
non-teaching hospitals describe M&M in their protocol (when existing), compared to 
only one third of the academic and teaching hospital protocols. Possibly, academic and 
teaching hospitals work more often according to evidence based principles of medicine 
approach. Although several studies do report higher complete evacuation rates after 
M&M treatment compared to misoprostol alone, there is insufficient evidence to draw 
firm conclusions.[13]
All respondents were willing to prescribe M&M treatment in the future with sufficient 
evidence that the success rate increases with an average of 21,7%. It should be mentioned 
that the current costs of mifepristone might be taken into account, so it may be that, since 
its costs are still decreasing, also lower success rates will be accepted in the near future. 
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Dutch women prefer medical treatment as long as the success rate exceeds 65%, and 
approximately 85% of women would prefer medical treatment if its complete evacuation 
rate would reach 80%.[25] This all together, assuming that a randomized controlled trial 
may confirm the superiority of M&M compared to misoprostol alone in case of EPF, 
implementation of M&M treatment will proceed fast.
Practical and research recommendations
Up until now, there is no Dutch guideline for treatment of EPF despite earlier recommen-
dations made by Verschoor et al.[19] Foreign guidelines concerning treatment in case of 
EPF exist, for example by the Royal College of Obstetricians and Gynecologist (RCOG) or 
the American College of Obstetricians and Gynecologists (ACOG). In contrast to other 
countries worldwide, it is standard procedure to wait for at least one week before starting 
any treatment because of a high change of spontaneous expulsion.[4, 26, 27] We therefore 
strongly advise to develop a national guideline describing the most optimal treatment 
regimen for the Dutch population. Preferably, this guideline should be developed by the 
Dutch association for Obstetrics and Gynecology (NVOG).
As mentioned before, a substantial part of the Dutch hospitals already prescribes mife- 
pristone in case of EPF. A sufficiently powered, multi-center, randomized, double blinded, 
and placebo-controlled trial will start second half of 2017 (http://www.clinicaltrials.gov: 
NCT03212352). This trial is necessary to confirm the hypothesis that M&M is superior to the 
use of misoprostol alone in terms of effectiveness (reduction of surgical interventions), 
risks of complications, patient satisfaction and costs. 
Conclusion
Although in most centers in the Netherlands a local protocol is present, there is still a large 
practice variation in the treatment of EPF. The use of M&M in EPF is not common practice, 
due to the lack of sufficient evidence. A proven increase in effectiveness of approximately 
20% after addition of mifepristone to the current treatment with misoprostol alone may 
cause all doctors to prescribe M&M in the future. 
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Abstract 
Study question
Is pre-treatment with mifepristone followed by misoprostol (M&M) superior to the use of 
misoprostol alone in terms of complete evacuation of the products of conception in early 
pregnancy failure?
Summary answer
The sequential combination of M&M in case of early pregnancy failure appears more 
effective than treatment with misoprostol alone regarding complete evacuation measured 
one week after treatment. This pilot study protocol reassured the methodology to confirm 
these findings by a large, prospective, randomized, and double-blinded trial.
What is known already
Several studies have been investigating the M&M treatment option, revealing success 
rates of 66 – 93% without serious adverse events. Unfortunately, these data are all derived 
from studies with a number of weaknesses including study design, inclusion criteria, and 
medical treatment starting directly after diagnosis without at least one week of expectant 
management.
Study design, size, duration
Two-centered, prospective, two-armed, randomized, double blinded, placebo-controlled 
trial at the department of Obstetrics and Gynecology of the Radboud University Medical 
Centre and Canisius-Wilhelmina Hospital in Nijmegen, the Netherlands. Forty women 
were randomized after giving informed consent between October 2016 and May 2017. 
Participants were randomized in a 1:1 ratio using computerized randomization tables. The 
randomization was conducted using block randomization and was stratified by hospital.
Participants/materials, setting, methods
Forty women with early pregnancy failure (6-14 weeks) wishing medical treatment after at 
least one week of expectant management were randomized. At day one, women were 
pre-treated with mifepristone 600mg or placebo tablets (both orally). At day three all 
women took standard medical treatment, which consisted of two doses of misoprostol 
400μg (four hours apart, orally). If no tissue was lost at day four, another two doses of 
misoprostol 400μg (four hours apart, orally) were taken. Ultrasound evaluation of 
treatment result was performed six to nine days after medical treatment started. Three 
digital questionnaires about quality of life and patient satisfaction were sent at baseline, 
four days and four weeks after treatment started.
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Main results and the role of chance
This pilot study confirmed feasibility of the study protocol. Complete evacuation was 
achieved in 13/19 (68,4%) of women in the M&M group versus 8/20 (40%) of women in the 
placebo group, which is not significantly different (p 0.057). The need for surgical intervention, 
was significantly lower in the M&M group as compared to the placebo group: 10,5% versus 
50% respectively (RR 1.789, 95% CI 1.124-2.848). No serious adverse events were reported 
in either group. Quality of life was similar in both groups. The majority of women, 84,6%, 
in the M&M group versus 62,6% of women in the placebo group, would choose medical 
treatment again. In the M&M group 92,3% and in the placebo group 75% of women would 
recommend medical treatment to a friend in case of EPF. 
Limitations, reasons for caution
A limitation of the pilot study is the small number of patients included.
Wider implications of the findings
Expectant management of at least one week is common practice in the Netherlands. In 
other countries treatment is started immediately after diagnosis. Therefore, our study 
results may not be globally generalizable for clinical practice. However, M&M treatment 
may also be superior to the use of misoprostol alone if started immediately after diagnosis. 
Study funding/competing interest(s)
This research was partly funded by Exelgyn (Groupe Nordic Pharma). The funders provided 
mifepristone and placebo tablets, and the costs of the pharmacy and CMO Arnhem- 
Nijmegen. The funders had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The authors have no conflicts of interest.
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Introduction
Early pregnancy failure (EPF) is a common complication of pregnancy, as approximately 
15% of all clinical pregnancies end in a miscarriage (6-14 weeks). The real incidence may be 
even higher, as not every case is being recognized clinically.[1-3] The incidence of EPF 
increases with age and because of rising childbearing age in the Western world, EPF is of 
increasing importance.
In the Netherlands, approximately 10,000 women per year undergo surgical or medical 
treatment after a minimum of one week of expectant management (prescribed in national 
guidelines) in order to remove the products of conception from the uterus.[4, 5] Surgical 
treatment (dilatation and curettage, D&C) is associated with risks of complications (0,01-1,2%; 
pelvic infection, cervical injury, uterine perforation, excessive bleeding, anesthesia, cervical 
insufficiency in following pregnancies) and costs.[6-8] Misoprostol is a synthetic prosta- 
glandin E1 analogue and is widely used in the management of EPF.[9-11] In the Netherlands, 
treatment is started after a minimum of one week of expectant management, because 
of an expected spontaneous complete evacuation rate of around 50% during the first 
weeks after diagnosis.[5, 12, 13] Unfortunately, after medical treatment with misoprostol, 
circa 50% of the women may still need a form of second treatment due to retained 
products of conception.[13, 14] 
A new medical treatment option combining mifepristone, an anti-progesterone and anti- 
glucocorticoid drug, followed by misoprostol (M&M treatment) seems more effective.[14, 15] 
Mifepristone increases the production of endogenous prostaglandin by the endometrium, 
as well as the sensitivity of the gravid uterus to exogenous prostaglandin, thus causing 
contractility of the myometrium, cervical softening and dilatation.[16, 17] At present, mife- 
pristone is licensed for four indications: medical termination of vital pregnancy (abortion) 
up tot 63 days of gestation, termination of vital pregnancy beyond first trimester, 
preparation for surgical abortion in the first trimester, and labor induction in fetal death 
in utero in the second and third trimester.[18] It appears reasonable to consider that, also 
for EPF, the sequential combination of mifepristone and misoprostol may be superior to 
misoprostol alone.[14-16]
Retrospective and anecdotal studies have been investigating the M&M treatment option, 
revealing success rates of 66 – 93% without serious adverse events.[3, 8, 19-25] All studies 
concluded that the combination of mifepristone and misoprostol might be an effective 
and safe alternative to surgical treatment. Unfortunately, these data are all derived from 
studies with a number of weaknesses including study design, inclusion criteria, and medical 
treatment starting directly after diagnosis without at least one week of expectant management. 
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A randomized, double blinded, placebo-controlled trial with a sufficient number of patients 
is required to test the hypothesis that the sequential combination of mifepristone with 
misoprostol is superior to misoprostol alone in case of EPF.[14, 15] The aim of this pilot 
study is to test feasibility and recruitment in order to improve quality of the final protocol 
of a larger study. 
Methods
A two-centered, prospective, two-armed, randomized, double blinded and placebo- 
controlled pilot trial was started, situated in a large academic (Radboud University Medical 
Centre) and a large teaching hospital (Canisius-Wilhelmina Hospital) in Nijmegen, the 
Netherlands, between October 2016 and May 2017. For this study, ethics approval (CMO 
Arnhem-Nijmegen, file number 2015-2264, NL 57892.091.16) and local approval by the 
Board of Directors of the two hospitals was obtained. All women gave written informed 
consent before study entry. Forty participants were followed in an outpatient clinic; 
hospital admission followed only if medically necessary. The trial was registered in the 
Dutch trial register, part of the Dutch Cochrane Centre (NTR6109), and in the European 
Clinical Trials Database (EudraCT, 2013-001554-10).
Patient selection and randomization
Woman with a diagnosis of EPF between 6 and 14 weeks of gestation, who had been 
managed expectantly for at least one week, were eligible for the trial. EPF was defined 
by transvaginal ultrasonography as an intra-uterine pregnancy and a crown-rump length 
≥ 6mm and no cardiac activity, or a gestational sac without embryonic pole. Women 
could be included one week after diagnosis or immediately in case of a discrepancy of at 
least one week between crown-rump length and calendar gestational age. Exclusion 
criteria were age < 18 years, hemodynamic instability, sign of infection, incomplete mis- 
carriage, high risk of thrombosis, contra-indications for mifepristone or misoprostol, 
interaction between study-medication and other medication or the inability to give informed 
consent. A computerized randomization list was prepared by an independent medical 
doctor not working at or connected to the trial. Participants were randomized in a 1:1 ratio 
to mifepristone or placebo using computerized randomization tables. The randomization 
was conducted using block randomization and was stratified by hospital to prevent any 
imbalance between groups in aspects of maternal care that may differ between centers. 
Treatment protocols
After informed consent and randomization, each patient received three (blinded) tablets 
containing 200mg mifepristone each or placebo (day 1). The mifepristone tablets and 
placebo were identical in appearance so neither the patient nor the physician knew which 
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product was taken. Both groups took the standard treatment with misoprostol at day 
three: two doses of misoprostol 400μg orally (four hours apart). If no tissue was lost by 
day four, again two doses of misoprostol 400μg orally (four hours apart) were taken. 
A transvaginal ultrasonography was performed six to nine days after treatment. Women 
were asked to document the amount of misoprostol tablets taken each day and possible 
side effects using a registration form (diary). Standard, validated questionnaires (Short 
Form 36, EuroQol-VAS and CSQ) were sent by e-mail at baseline (day 1), four days (day 5) 
and four weeks (day 29) after treatment started. The blinding of patients and physicians 
for treatment arm was maintained until the follow-up (questionnaire four weeks after 
treatment) of the last included patient was completed.
Outcome measures 
Primary and secondary outcome measures were extracted from the patient medical record, 
diary, digital questionnaires and/or case report form. The primary outcome parameter, 
complete (success) or incomplete (failure) evacuation, was determined by transvaginal 
ultrasonography one week (six to nine days) after medical treatment. An endometrial 
thickness < 15mm (maximum anterior-posterior diameter) or no evidence of retained 
products of conception using only the allocated therapy by randomization was considered 
as complete evacuation.[9, 13, 26-28]
Secondary outcome parameters included complications, side effects and patient satisfaction. 
Each patient received a registration form (diary) to document the amount of misoprostol 
tablets taken and possible side effects. The treating gynecologist documented complications 
and side effects using the case report form (CRF). Quality of life was measured at baseline, 
four days and four weeks after treatment started using standard, validated questionnaires: 
EuroQol-VAS and Short Form 36. Patient satisfaction with treatment was measured four 
weeks after treatment using the Client Satisfaction Questionnaire (CSQ-8). 
Statistical analyses
Data were analyzed according to intention to treat method. The main outcome variable 
was complete evacuation after medical treatment and was assessed by calculating 
success rates, relative risks and 95% confident intervals in both groups. To evaluate the 
potential of each of the strategies, we also performed a per protocol analysis, taking into 
account only those cases that were treated according to protocol.
SPSS version 24 was used for data analysis. Differences between groups were analyzed using 
the Pearson’s chi-square test or the Fisher’s exact test for categorical variables. Mann- 
Whitney U test was used for non-normally distributed metric variables. Logistic regression, 
univariate, and multivariate analysis were performed to identify factors that were associated 
with treatment success. P-values smaller than 0.05, were considered significant. 
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Results
Forty women were included and randomized: twenty women were allocated to mife- 
pristone and twenty to placebo (figure 1). Since both arms are followed by misoprostol, 
treatment arms will further be called as “M&M” and “placebo” group. Baseline characteristics of 
the two groups were comparable (e.g. not significant, table 1). One woman in the M&M 
group was excluded post-randomization because she did not meet the inclusion criteria, 
which was detected after randomization. She was included after only one day of expectant 
management instead of at least one week (figure 2). So, 39 women were included in the 
intention to treat analysis. 
Two women, one in each arm, who gave informed consent, experienced spontaneous 
miscarriage before medical treatment started. In the M&M group, one woman, who was 
included after informed consent, changed her mind afterwards and did not take the study 
medication. Another woman in the M&M group was not treated conform treatment 
protocol; she inserted misoprostol vaginally (two doses of 800μg) 22 hours after taking 
the study medication instead of swallowing misoprostol orally (400μg) 36-48 hours later. 
So, taken into account two spontaneous miscarriages and two protocol deviations, 35 women 
were treated conform study protocol and included in per protocol analysis (figure 2). 
One woman in the M&M group did not show up at the appointment six to nine days after 
treatment; she visited the hospital five weeks later and underwent transvaginal ultra-
sonography showing an endometrial thickness < 15mm without additional therapy. In the 
placebo group, one woman had an ultrasound at day 4 because she didn’t want to wait 
any longer. A gestational sac was still intra-uterine; D&C was performed at day 11. The mean 
time between the start of medical treatment and performing ultrasonography to determine 
treatment success was 9.37 days (range 3 – 34 days).
In the M&M group, 13/19 (68,4%) had a complete evacuation one week after medical 
treatment. In the placebo group, 8/20 (40,0%) had a complete evacuation after one week, 
which is not significantly different (p 0.057, table 2). In addition to intention-to-treat 
analysis, per protocol analysis revealed success rates of 10/16 (62,5%) in the M&M group 
versus 7/19 (36,8%) in the placebo group (p 0.139). No differences in primary outcome were 
observed after adjusting for the difference between ultrasound gestational age, duration of 
expectant management, parity, prior miscarriages or prior successful misoprostol treatment.
At the time of determining the main study outcome and the need for additional treatment 
in case of an incomplete evacuation (one week after treatment), physician and patient 
were both still blinded. In total, 18 women underwent additional treatment and reached 
complete evacuation afterwards (table 3). In 1/19 (5,2%) of the M&M group versus 9/20 
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(45%) of the placebo group a gestational sac was still intrauterine, concluding that medical 
treatment has had no effect at all. Five women (5/18, 27,8%) reached complete evacuation 
after expectant management until approximately six weeks after treatment. Two women 
were treated with misoprostol treatment again and received two more doses of miso- 
prostol (800μg vaginally), of which one woman (placebo group) underwent emergency 
D&C because of heavy vaginal bleeding after the second misoprostol treatment. The need 
for D&C was significantly lower in the M&M group as compared to the placebo group: 
2/19 (10,5%) versus 10/20 (50%) respectively (p 0.008, RR 1.789, 95% CI 1.124-2.848). D&C 
Figure 1  CONSORT flow diagram
Assessed for eligibility 
Excluded (n=0)
(n=40)
Assessed for eligibility 
(n=40)
Allocated to mifepristone (n=20)
Received mifepristone (n=18)
Did not receive mifepristone (n=2)
- Spontaneous miscarriage before
 treatment (n=1)
- Did not take mifepristone (n=1) 
Allocated to placebo (n=20)
Received placebo (n=19)
Did not receive placebo (n=1)
- Spontaneous miscarriage before
 treatment (n=1)  
Lost to follow-up (n=0)
Discontinued intervention (n=0) 
Lost to follow-up (n=0)
Discontinued intervention (n=0) 
Analyzed ITT (n=19)
Excluded from all analysis (n=1)
- Did not meet inclusion
 criteria discovered after
 randomization (n=1)
Analyzed PP (n=16) 
Analyzed ITT (n=20)
Analyzed PP (n=19)
En
ro
lm
en
t
A
llo
ca
tio
n
Fo
llo
w
-u
p
 
A
na
ly
si
s
85
RANDOMIZED CONTROLLED PILOT STUDY
5
Table 1  Baseline characteristics
Baseline characteristics M&M
N=19
Placebo 
N=20
Significance 
(P-value)
Age (years) 
Mean (SD)
Range 
Unknown
30,53 (5,274)
21 – 39  
0
32,00 (2,772)
28 –37
0
0.288 
Diagnosis
Embryo without cardiac activity
Anembryonic gestation
13 (85%)
6 (15%)
17 (85%)
3 (15%)
0.219 
Gestational age based on amenorrhea (days)
Mean (SD)
Range
Unknown
73,76 (11,503)
56 – 96 
2
73,50 (10,541)
56 – 100 
0
0.760
Gestational age based on ultrasound (days)
Mean (SD)
Range
Unknown
52,05 (10,799)
36 – 78 
0
49,00 (7,688)
38 – 64 
1
0.438
Duration expectant management (days)
Mean (SD)
Range
Exact period unknown
20,94 (12,235)
7 – 53
2
24,21 (9,953)
12 – 50 
1
0.302 
Number of previous pregnancies
0
1
≥2 
8 (42,1%)  
5 (26,3%)  
6 (31,6%)
10 (50%)  
4 (20%)  
6 (30%)
0.857
Parity
0
1
2
12 (63,2%)  
6 (31,6%)  
1 (5,3%)
11 (55%)  
5 (25%)  
4 (20%)
0.361  
Prior miscarriage 
Yes 
No
8 (40%)
12 (60%)
6 (30%)
14 (70%)
0.507 
Prior misoprostol treatment
Yes, successful
Yes, unsuccessful 
No 
2 (N=8, 25%) 
0 
6 (N=8, 75%)
1 (N=6, 20%)
0
5 (N=6, 80%)
1.000 
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Figure 2  Flow of participants until one week after treatment
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was mainly performed (8/12, 66,7%) because of a persistent intrauterine gestational sac, 
this was significant different between both groups: only one woman in the M&M group 
versus seven women in the misoprostol group (p 0.044). Three women in the placebo group 
needed D&C because of heavy vaginal bleeding, of which one woman underwent D&C at 
day three because of heavy vaginal bleeding (750cc) and sonographic retained products 
of conception. Another woman was scheduled for D&C a few days after determining the main 
study outcome, however, in the meantime she underwent emergency D&C because of heavy 
vaginal bleeding. Also, per protocol analysis revealed a significant difference between the 
need for D&C in the M&M and placebo group: 2/16 (12,5%) versus 10/19 (52,5%, p 0.013). 
During treatment, women in the M&M group reported significantly more blood loss than 
women in the placebo group (p 0.007, figure 3). In the M&M group, 15/19 (78,9%) described 
their blood loss as “more than a menstruation” and 1/19 (5,3%) as “less than a menstruation”. 
Table 2  Complete evacuation rates
M&M group,  
n/N (%)
Placebo group,  
n/N (%)
P value
Complete evacuation rate, total 13/19 (68,4) 8/20 (40) 0.057
Anembryonic gestation 4/6 (66,7) 2/3 (66,7) 1.000
Embryo without cardiac activity 9/13 (66,7) 6/17 (35,3) 0.070
Table 3  Additional treatment resulting in complete evacuation
M&M group,  
n/N (%)
Placebo group,  
n/N (%)
P value
Expectant management 4/19 (21,2) 1/20 (5) 0.134
Residua 4/4 (100) - -
Persistent gestational sac - 1/1 (100) -
Medical treatment 0/19 (0) 1/20 (5) -
Persistent gestational sac - 1/1 (100) -
D&C 2/19 (10,5) 10/20 (50) 0.008
Residua 1/2 (50) 0/100 (0) 0.487 
Persistent gestational sac 1/2 (50) 7/10 (70) 0.044
Hemorrhage - 3/10 (30) 0.23 
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In the placebo group, 8/20 (40%) classified their blood loss as “more than a menstruation” 
and 9/20 (45%) as “less than a menstruation”. However, one week later, during follow-up, 
this difference was no longer seen (p 0.081). The bleeding had stopped or was described 
as less than a menstruation in the M&M group in 16/18 (84,2%) and in the placebo group 
in 14/20 (70%). No blood transfusions during treatment and follow-up were needed.
Side effects in both groups were mainly experienced at day three and four during miso- 
prostol treatment (figure 3). Nausea and gastrointestinal side effects were most reported 
in both groups. Concerning the reported side effects, only dizziness was significantly 
higher in the placebo group (p 0.047). The use of analgesics was not significant different 
between both groups.
Client satisfaction questionnaire
In total, 115 digital questionnaires were sent of which 75,4% in the M&M group, and 89,7% 
in the placebo group were completed. Women in both groups were equally satisfied with 
medical treatment (figure 4). In case of EPF, 11/13 (84,6%) women in the M&M group versus 
10/16 (62,6%) women in the placebo group would choose the same treatment again. 
In the M&M group 12/13 (92,3%) and in the placebo group 12/16 (75%) would recommend 
medical treatment to a friend in case of EPF.
Short Form-36 and EuroQol visual analogue scale
Health related quality of life, measured using short-form 36 (SF-36) and EuroQol-VAS as 
baseline, four days and four weeks after treatment started, was not significant different 
between the M&M and placebo group. In both groups, six dimensions of SF-36 were 
significantly different over time, and were most impaired four days after treatment (figure 5). 
Figure 3   Side effects during medical treatment. *Defined by patients as more than  
a menstruation
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No side effects
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Figure 4   Satisfaction with treatment
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Figure 5   Dimensions of Short Form 36
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Mental health, general health and general health change were not significant different 
over time. In the M&M group, no significant differences in health dimensions were seen 
between successful and unsuccessful treatment. Women in the placebo group with an 
unsuccessful treatment had significantly more pain, more impaired physical functioning 
and lower scores at the EuroQol-VAS compared to women with a successful treatment. 
Discussion / comment
Main findings
This randomized, double blinded, placebo controlled pilot study was designed to prepare 
for a sufficiently powered definitive trial, comparing pre-treatment with mifepristone 
versus placebo followed by misoprostol in women with EPF between 6 and 14 weeks of 
gestation after a minimum of one week of expectant management. Accrual of study 
patients was as expected with completion of forty patients within seven months in one 
academic and one teaching hospital in the Netherlands. This pilot clinical trial showed an 
inclusion rate as expected, and almost no data loss: only one patient didn’t show up at 
the follow-up appointment. Complete evacuation measured one week after treatment 
was not significantly different: 68,4% in the M&M group versus 40% in the placebo group. 
The need for D&C after medical treatment was significantly different, 10,5% in the M&M 
group versus 50% in the placebo group. A significant difference was reported between 
the incidence of persistent gestational sac: 1 woman in the M&M group versus 9 women 
in the placebo group. No serious adverse events were reported. More than 80% of the 
digital questionnaires were completed. Concerning patient preferences, 84,6% women in 
the M&M group versus 62,6% women in the placebo group, would choose medical 
treatment again and 92,3% in the M&M group versus 75% in the placebo group would 
recommend medical treatment to a friend in case of EPF.
Strengths and Limitations 
This pilot study was randomized, double blinded and placebo controlled. Our baseline 
data showed no significant differences between the two treatment groups. A uniform 
treatment protocol and CRF were available describing diagnosis of early pregnancy failure, 
therapy counseling and patient information. There was a clear and objective primary and 
secondary outcome definition. A limitation of the pilot study is of course the small number 
of patients included.
Interpretation
Regarding medical treatment regimens, different doses of mifepristone and misoprostol 
and routes of administration of misoprostol are described in literature. Until now, the 
World Health Organization (WHO) advises 200mg mifepristone in case of termination of a 
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vital pregnancy in the first trimester.[29] However, based on phase 2 trials for medical 
termination of a vital pregnancy up to 63 days gestation, a dose of mifepristone 600mg is 
advised by the manufacturer Exelgyn (Groupe Nordic Pharma, France).[16] Phase 2 trials 
showed that 600mg mifepristone was superior to the 200mg dose in terms of complete 
abortion in case of medical abortion of a vital pregnancy (89% versus 63%).[30, 31] 
A Cochrane review included only one trial comparing low and high doses of mifepristone 
in case of medical abortion, reporting no significant difference in failure and side effects.
[32, 33] The recommendation of 200mg mifepristone by the WHO is probably due to 
formerly high costs (approximately 20 euro for one tablet containing 200mg) in the 
context of low-resource countries. Since the patent on mifepristone has expired, the costs 
of mifepristone are decreasing drastically (current price in the Netherlands € 11,66). 
To achieve the desired optimal effect, a dose of 600mg mifepristone was used in our pilot 
trial. The effect of mifepristone develops over a time period of 24-48 hours; therefore 
prostaglandins were administered 36-48 hours later.[16, 32]
Misoprostol is part of the standard treatment and different treatment regimens (dose and 
route of administration) are described in literature. In case of EPF, the International 
Federation of Obstetrics and Gynecology (FIGO) advises misoprostol 800µg per vaginam 
every 3 hours (maximum of 2 doses) or 600µg sublingual every 3 hours (maximum of 
2 doses).[29] However, recent reviews conclude that further research is necessary to 
determine the most optimal treatment regimen.[34-36] Vaginal application of misoprostol is 
widely accepted. However, oral misoprostol is advised by the manufacturer of mifepristone 
(Exelgyn) if combined with mifepristone, based on a significant lower infection rate in case 
of medical abortion after changing the regime of vaginal to oral administration.[37] When 
pharmacologically comparing oral and vaginal administration of misoprostol, oral 
misoprostol leads to a more rapid absorption and higher peak levels.[37] Gastrointestinal 
side effects are dose and interval dependent, higher doses and short intervals may lead to 
an increase in symptoms.[38, 39] Although one would suspect that oral misoprostol leads to 
more side effects due to higher peak concentrations, a similar incidence of vomiting, nausea, 
diarrhea and fever was found in a recent Cochrane review.[40] However, it should be 
mentioned that the quality of evidence is low. In contrast to this recent review regarding EPF, 
Cochrane reviews including incomplete miscarriages or termination of vital pregnancies in 
the first trimester, report significantly more nausea and diarrhea after oral misoprostol.[32, 
41] Regarding effectiveness, a Cochrane review reported that misoprostol 800μg orally is 
equally effective compared to misoprostol 800μg vaginally.[3, 40] A split dosage of 
misoprostol (two or three doses of 400μg) has been reported to be similar in success rates 
as a protocol using 800μg at once.[32, 40] However, the mean time to expulsion was longer 
after oral intake of misoprostol compared to vaginal application.[41, 42] Clinical studies 
comparing oral and vaginal misoprostol have found increased satisfaction with the oral 
route because it is easy to use and avoids any unnecessary vaginal examinations.[44, 45] 
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Taken all together, we have chosen oral administration of misoprostol because it seems 
equally effective compared to vaginal application, is easy to use, and is preferred by patients. 
Since a split-dose regimen is equally effective, but would possibly lead to a lower incidence 
of side effects, we have chosen a split dose of misoprostol 400μg. 
The main study endpoint was determined by ultrasonography one week after medical 
treatment was started. With regards to the follow-up of women receiving medical treatment: 
there are no clear recommendations about the time period and optimal diagnostic tool to 
define success. Assessment after one week was common practice in the Netherlands at 
the time of drafting the study protocol (J. van den Berg, Dutch survey 2017, unpublished data). 
And as reported in our results section, there was a significant difference in persistent 
intrauterine gestational sac one week after treatment between both groups. Therefore, 
performing ultrasonography shortly after medical treatment (one or two weeks) is important 
to determine treatment failure and to offer further treatment to patients on short-term. 
Regarding the presence of intrauterine remnants, ultrasonography seems to be of limited 
value. Recent studies do not provide any clear evidence which endometrial thickness 
corresponds best to the presence of intrauterine pregnancy remnants.[46, 47] A study by 
Rulin concludes that in case of a maximum anterior-posterior diameter of 15 mm or less, 
retained products are less likely to be confirmed histologically.[26] Also a recent study by 
Lavecchia et al demonstrated that in women with a cavity anterior-posterior distance of 
less than 15 mm, 87,1% did not need D&C afterwards.[27] In contrast, a study by Creinin 
reported a wide range of endometrial thickness (1-31mm) two weeks after expulsion of 
the gestational sac and a decreasing endometrial thickness over time, suggesting that clinical 
signs and symptoms should guide treatment decisions after medical treatment.[48] 
Evidence is growing that D&C may have major long-term consequences such as intra- 
uterine adhesions and increased spontaneous preterm birth rates in subsequent pregnancies. 
[13, 49, 50] The recent Dutch “MisoREST” study compared D&C and expectant management 
in case of an incomplete evacuation after misoprostol treatment defined as intra-uterine 
remnants at ultrasonography or an anterior-posterior diameter exceeding 10 mm.[46] 
These authors conclude that expectant management should be considered as first line 
treatment in women with incomplete evacuation after misoprostol treatment for EPF.[51] 
As a result of the aforementioned, we have made adjustments in the definitive protocol 
concerning the primary endpoint. 
Practical and research recommendations
Based on current data, we have made recommendations for improvements of the 
definitive, sufficiently powered study protocol for a multicenter, randomized, double blind 
and placebo controlled trial.
93
RANDOMIZED CONTROLLED PILOT STUDY
5
• Ultrasonography will be performed two weeks after medical treatment to evaluate the 
uterine cavity shortly after medical treatment. In case of a so-called empty uterus by 
ultrasonography (TED < 15mm), no further evaluation is necessary. In case of suspected 
retained products of conception, expectant management is advised for another four 
weeks. Ultrasonography will be performed six weeks after medical treatment to determine 
complete or incomplete evacuation. 
• During six weeks after treatment, clinical signs and symptoms should guide treatment 
decisions. In case of asymptomatic patients, no additional examination or treatment is 
necessary until six weeks later. Additional treatment could be necessary in case of: no 
reaction after treatment (no bleeding or tissue loss), heavy or continuous bleeding, 
persistent abdominal pain, intra-uterine infection or on patient request. 
A longer period of expectant management is in line with patient preferences in the 
Netherlands as shown by the recent “MisoREST-study”, which was stopped prematurely 
because of strong preferences for expectant management instead of D&C in case of 
incomplete miscarriage after medical treatment.[46, 51] For expectant management to be 
safe, patients have to be able to contact and visit a nearby hospital immediately. 
Conclusion
The sequential combination of mifepristone and misoprostol in case of early pregnancy 
failure appears more effective than treatment with misoprostol alone regarding complete 
evacuation after one week. This pilot study protocol reassured the methodology to 
confirm these findings by a large, prospective, randomized, and double-blinded trial, 
which will start second half of 2017. 
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CHAPTER 6
Abstract
Background
Early pregnancy failure (EPF) is a common complication of pregnancy. If women do not 
abort spontaneously, they undergo medical or surgical treatment in order to remove the 
products of conception from the uterus. Curettage, although highly effective, is associated 
with risks of complications; medical treatment with misoprostol is a safe and less expensive 
alternative. Unfortunately, after one week of expectant management, the current treatment 
with misoprostol has a complete evacuation rate of approximately 50%. Medical treatment 
may be improved by pre-treatment with mifepristone; its effectiveness has already been 
proven for other indications of pregnancy termination. This study will test the hypothesis 
that, in EPF, the sequential combination of mifepristone with misoprostol is superior to 
the use of misoprostol alone in terms of complete evacuation (primary outcome), patient 
satisfaction, complications, side effects and costs (secondary outcomes).
Methods
The trial will be performed multi-centered, prospectively, two-armed, randomized, double- 
blinded and placebo-controlled. Women with confirmed EPF by ultrasonography (6-14 
weeks), managed expectantly for at least one week, can be included and randomized to 
pre-treatment with oral mifepristone (600mg) or oral placebo (identical in appearance). 
In both arms pre-treatment will be followed by oral misoprostol, which will start 36-48 
hours later consisting of two doses 400μg (four hours apart), repeated after 24 hours if no 
tissue is lost. 460 women will be randomized in a 1:1 ratio, stratified by center.
Ultrasonography two weeks after treatment will determine treatment effect on short term. 
An expectant management is advised until six weeks after treatment when the primary 
endpoint, complete or incomplete evacuation, will be determined. A sonographic endometrial 
thickness < 15mm and no evidence of retained products of conception using only the 
allocated therapy by randomization, is considered as successful treatment result. 
Secondary outcome measures (patient satisfaction, complications, side effects and costs) 
will be registered using a case report form, patient diary and validated questionnaires 
(Short Form 36, EuroQol-VAS, Client Satisfaction Questionnaire). 
Discussion
This trial will answer the question if, in case of EPF, medical management with sequential 
mifepristone and misoprostol is more effective than misoprostol alone to achieve complete 
evacuation of the products of conception.
Trial registration
EudraCT number: 2017-002694-19 Clinicaltrials.gov: NCT03212352
Trialregister.nl: NTR 6550 Toetsingonline.nl: NL 62449.091.17
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Background
In the Netherlands, every year more than 10.000 women with early pregnancy failure (EPF) 
undergo surgical or medical treatment in order to remove the products of conception 
from the uterus.[1] For many years, surgical treatment (dilatation and curettage, D&C) has 
been standard treatment.[2] However, D&C is associated with risks of complications (uterine 
perforation, pelvic infection, excessive bleeding, anesthesia, intra-uterine adhesions, cervical 
injury or cervical insufficiency in following pregnancies) and high costs.[3-7]
The Royal College of Obstetricians and Gynecologists as well as the “American College of 
Obstetricians and Gynecologists” recommend medical methods as a safe, effective and 
acceptable alternative (evidence level A).[8, 9] Misoprostol is used for several obstetric and 
gynecologic indications, including EPF, due to uterotonic properties leading to myometrial 
contractions and ripening and dilatation of the cervix.[10] For medical treatment, the Inter- 
national Federation of Gynecology and Obstetrics (FIGO) recommends the prescription 
of two doses misoprostol 800µg administered vaginally (three hours apart) or two doses 
misoprostol 600µg sublingual (three hours apart).[11, 12] Unfortunately, if a minimum of 
one week of expectant management is followed by misoprostol treatment, half of the 
women still have to undergo D&C due to retained products of conception and thus still 
may be exposed to the risks of complications associated with D&C.[2, 13-15] 
Mifepristone is a progesterone antagonist and its administration during pregnancy increases 
the production of endogenous prostaglandin by the endometrium, the sensitivity of the 
gravid uterus to exogenous prostaglandin, the contractility of the myometrium, and 
cervical softening and dilatation.[16, 17] For other indications, such as labor induction in 
case of fetal death after the first trimester, and also for medical termination of vital pregnancy 
(medical abortion), the sequential combination of mifepristone with misoprostol has been 
shown superior to the use of misoprostol alone.[18, 19] So, it appears reasonable to 
consider mifepristone with misoprostol to be superior to misoprostol alone in case of EPF 
(non-vital pregnancy in the first trimester).
Several groups have been investigating the sequential combination of mifepristone with 
misoprostol in EPF, and reported success rates of 66 – 93% without any serious adverse 
events.[7, 11, 13, 20-27] Unfortunately, these studies were small and flawed by different 
inclusion criteria and treatment regimens or retrospective study design.[13] A retrospective 
study performed by our research group including 301 women with EPF between 6-14 
weeks of gestation, reported success rate of 67% in the intervention group (mifepristone 
+ misoprostol, M&M) versus 40% in the control group (placebo + misoprostol). However, 
to develop evidence based treatment regimen, a sufficiently powered, randomized, 
double blinded, and placebo-controlled trial is required. 
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Methods / Design
Study aim and design 
The aim of this study is to compare addition of mifepristone to the standard treatment 
with misoprostol in terms of complete evacuation of products of conception from the 
uterus, patient satisfaction, complications, side effects and costs. The trial will be 
performed multi-centered in the Netherlands and will be conducted prospectively, 
two-armed, randomized (1:1 ratio), double blinded and placebo-controlled. Participating 
hospitals can be district, teaching or third referral (academic) hospitals. Participants are 
followed in an outpatient clinic; hospital admission follows only if medically necessary. 
Ethical approval to conduct the study is obtained at the regional medical-ethical 
commission (CMO Arnhem-Nijmegen). 
Participants and eligibility criteria
We will study women aged above 18 years with a diagnosis of EPF between 6 and 14 weeks 
of gestation. EPF is diagnosed by transvaginal ultrasonography describing:
- A crown-rump length ≥ 6mm and no cardiac activity OR 
- A crown-rump length < 6mm and no fetal growth at least one week later OR 
- A gestational sac with absent embryonic pole for at least one week. 
A minimum of one week of expectant management results in spontaneous complete 
abortion rates of 50%, and is common practice in the Netherlands.[2, 28] Therefore, 
women can only be included at least one week after diagnosis. However, in case of a 
discrepancy of at least one week between crown-rump length and the calendar 
gestational age, patients can be included immediately because the one-week of 
expectant management has already passed. 
Exclusion criteria are age < 18 years, hemodynamic instability, sign of infection, incomplete 
miscarriage, high risk of thrombosis, contra-indications for mifepristone or misoprostol, 
interaction between study-medication and other medication or the inability to give 
informed consent. 
Procedures, recruitment, randomization, and collection of baseline data
Women visiting a hospital in case of EPF are identified and approached to participate in 
the trial by their treating physician. Trained staff will counsel patients, inform about the 
aims, methods, reasonable anticipated benefits and potential hazards of the study, hand 
out the patient information letter, and offer 24 hours to reflect. Patients will also be 
informed about the off-label use of mifepristone and misoprostol. Participation is 
voluntary and patients may withdraw consent to participate at any time during the study. 
The investigator can decide to withdraw a subject from the study for urgent medical 
reasons. Baseline demographics, obstetric and medical history are recorded for all women 
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at the time of randomization using a case report form. After obtaining written informed 
consent, randomization can be performed. 
The Clinical Trial Unit of the Radboudumc will coordinate randomization. Subjects will be 
randomized in a 1:1 ratio to mifepristone 600mg oral or placebo using computerized 
randomization tables. The randomization will be conducted using block randomization 
and will be stratified by hospital. After randomization a unique study number will be 
assigned corresponding with a study package available in the participating center 
containing the blinded study medication. The placebo and mifepristone tablets are 
identical in appearance so neither the patient nor the physician will know which product 
is taken. Only the pharmacy will know which medication or placebo the patient receives. 
Blinding, distribution and labeling of the study medication packages will be coordinated 
by the clinical trial unit in the Radboudumc (Nijmegen). A sealed list with the label codes 
will be available in case of emergencies. These data will be disclosed to the principal 
investigators only after data on all outcome parameters have been collected. Regarding 
misoprostol, the treating physician will prescribe these tablets as usual, which woman can 
retrieve at their own pharmacy.
Interventions and follow-up
After informed consent and randomization, each patient receives three (blinded) tablets 
containing 200mg mifepristone each or placebo (day 1, figure 1). Apart from the study 
medication, management of participants will be similar in both groups. At day three 
(36-48 hours later), two doses of misoprostol 400μg orally (four hours apart) will be taken 
at home. If no tissue is lost by day four, two more doses of oral misoprostol 400μg orally 
(four hours apart) will be taken at home. 
Regarding mifepristone, the World Health Organization advises mifepristone (200mg) in 
combination with misoprostol in case of termination of a vital pregnancy in the first 
trimester.[29] Reasons for the lower dosage of mifepristone are not mentioned in their 
guideline; one could imagine it’s because of the, until recent, high costs of mifepristone in 
the context of low-resource countries. However, two phase 2 trials showed that 600mg 
mifepristone was superior to the 200mg dose in terms of complete abortion in case of 
termination of a vital pregnancy (89% versus 63%).[30, 31]
Concerning misoprostol, many different treatment regimens have been described with 
various routes of administration and doses. Up until 2014, 23 different treatment regimens 
(dosages and routes of administration) were used in the Netherlands, and in many 
hospitals even more than one treatment regimen existed simultaneously.[32] Several 
reviews conclude that research is still necessary to determine the most optimal treatment 
regimen.[33, 34] Vaginal application of misoprostol is widely accepted. However, oral 
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misoprostol is advised by the manufacturer of mifepristone (Exelgyn) if combined with 
mifepristone, based on a significant lower infection rate in case of medical abortion after 
changing the regime of vaginal to oral administration.[35] When pharmacologically 
comparing oral and vaginal administration of misoprostol, oral misoprostol leads to a 
more rapid absorption and higher peak levels.[36] Gastrointestinal side effects are dose 
and interval dependent, higher doses and short intervals may lead to an increase in 
symptoms.[36, 37] Although one would suspect that oral misoprostol leads to more side 
effects due to higher peak concentrations, an equal incidence of vomiting, nausea, 
diarrhea and fever was reported in a recent Cochrane review (submitted).[38] However, it 
should be mentioned that the quality of the included studies is low. In contrast to this 
recent Cochrane review concerning EPF, reviews including incomplete miscarriages or 
termination of vital pregnancies in the first trimester do report significantly more nausea 
and diarrhea after oral misoprostol.[19, 39] 
Regarding effectiveness of misoprostol treatment, a Cochrane review reported that 
misoprostol 800μg orally is equally effective compared to misoprostol 800μg vaginally.[11, 
38] A split dosage of misoprostol (two or three doses of 400μg) has been reported to be 
similar in success rates as a protocol using 800μg at once.[19, 38] However, the mean time 
to expulsion was longer after oral intake of misoprostol compared to vaginal application.
[40, 41] Clinical studies comparing oral and vaginal misoprostol have found increased 
satisfaction with the oral route because it is easy to use and avoids any unnecessary 
vaginal examinations.[42, 43] In our study protocol, the oral route is chosen because it 
appears equally effective compared to vaginal application, is easy to use, and an increased 
patients satisfaction.[42] Since a split-dose regimen is equally effective, but may lead to a 
lower incidence of side effects, we have chosen a split dose of misoprostol 400μg. Thereby, 
if the first dose of misoprostol 400μg leads to complete expulsion of the gestational sac, 
the second dose doesn’t have to be taken.
With regards to the follow-up of women receiving medical treatment, there are no clear 
recommendations about the time period and optimal diagnostic tool to define success. 
Ultrasonography seems to be of limited value in predicting the presence of intrauterine 
remnants. Recent studies do not provide any clear evidence which endometrial thickness 
corresponds best to the presence of intrauterine pregnancy remnants.[15, 44] A study by 
Rulin concludes that in case of a maximum anterior-posterior diameter of 15 mm or less, 
retained products are less likely to be confirmed histologically.[45] Also a recent study by 
Lavecchia et al reported that a cavity anterioposterior distance of more than 15mm was 
associated with the need for D&C and an unplanned return to the emergency department.
[46] However, another study by Creinin showed a wide range of endometrial thickness 
(1-31mm) two weeks after expulsion of the gestational sac and a decreasing endometrial 
thickness over time. The authors suggest that clinical signs and symptoms should guide 
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Figure 1   Flowchart of study procedures. *If no tissue is lost by day four, two more 
doses of misoprostol will be taken at day four
Women with early pregnancy failure, AD 6-14 weeks,
after one week of expectant management  
Informed consent 
Randomisation
Day 1 : mifepristone 600mg or placebo 
Day 3 (+ 4*) : two doses misoprostol
400µg 
Ultrasonography
6 weeks after treatment
TED < 15 mm TED > 15mm OR
needed additional treatment
Day 15 - 20 : ultrasonography
TED > 15 mm :
4 more weeks of
expectant management
Complete gestational
sac intra-uterine OR
additional treatment needed
TED < 15 mm
Complete
evacuation
Complete
evacuation
Incomplete
evacuation
Incomplete
evacuation
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treatment decisions after medical treatment.[47] An expectant management in case of an 
endometrial thickness more than 15mm one week after medical treatment is advised 
on the basis of recent findings by the Dutch nationwide MisoREST-study,[14, 15] 
The MisoREST-study investigated whether curettage is more effective than expectant 
management in case of an incomplete evacuation (sonographic endometrial thickness 
> 10mm) one week after misoprostol treatment. The MisoREST-study concludes that 
expectant management until six weeks after medical treatment is safe, effective in 
approximately 80% of patients, and that women have a clear preference for expectant 
management instead of curettage.[14]
In our trial, ultrasonography will be performed between day 15 and 20 to evaluate the first 
treatment effect (figure 1). In case of a total endometrial thickness (TED) < 15mm by ultra-
sonography, no further evaluation is necessary and treatment is considered as successful. 
In case of retained products of conception (TED > 15mm) expectant management is 
advised, with consent from the patient, for another four weeks. Patients are able to contact 
their hospital 24h a day in case of any questions, complaints or emergencies. During these 
weeks of expectant management, clinical signs and symptoms should determine whether 
additional treatment (curettage) is necessary. If successful curettage has been performed 
after medical treatment, no further examinations for the purposes of the study project 
are necessary. Six weeks after treatment, ultrasonography will be performed to evaluate 
endometrial thickness. In case of an endometrial thickness > 15mm six weeks after 
treatment, further treatment will be according to local protocol and patient preferences. 
Additional treatment may be expectant, medication or surgical (hysteroscopy or D&C).
Anti-D prophylaxis will be given if necessary as part of the standard treatment, following 
the NVOG-guideline “Erytrocytenimmunisatie en zwangerschap”.[48]
Outcome measures 
Primary and secondary outcome measures will be extracted from routine clinical parameters 
in the patient medical record and patient diary and recorded in a digital case report form. 
A two-step method will be used to determine treatment success. Ultrasonography will be 
performed two weeks after medical treatment to determine treatment failure defined as 
a complete gestational sac intrauterine. The definite primary study outcome, complete 
(success) or incomplete (failure) evacuation, will be determined six weeks after treatment.
[2, 8, 45, 47, 49-51] A successful medical treatment will be considered in case of an ultra-
sonography showing a TED < 15mm (maximum anterior-posterior diameter), two or six weeks 
after medical treatment and no evidence of retained products of conception using only the 
allocated therapy by randomization. 
Secondary outcomes include patient satisfaction, complications, side effects and costs. 
Secondary outcome measures are subtracted from the medical record, patient diary 
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and (validated) digital questionnaires. At baseline, day five, and two and six weeks after 
treatment started, questionnaires will be sent by email. To measure the quality of the 
health status of the patients, two so-called health-related quality of life (HRQoL) instruments 
will be used: the Short Form 36 health survey and the EuroQol-5D, both available in a Dutch 
translation. Patient preferences and satisfaction with treatment will be measured using 
The Client Satisfaction Questionnaire (CSQ-8, digital) two and six weeks after treatment. 
Economic evaluation
A cost-effectiveness analysis will be performed, from a societal perspective. To evaluate 
which medical treatment strategy is cost-effective, volumes of health care consumed will 
additionally be measured prospectively alongside the clinical trial together with cost 
associated with productivity losses. Costs of medical interventions (direct costs) and costs 
resulting from productivity loss (indirect costs) will be taken into account. Resource uses 
will be recorded in the case report forms. Standardized unit costs will be calculated using 
the Dutch manual for costing in economic evaluations. 
Statistical issues
Sample size calculation
Based on retrospective data in the Radboud University Medical Centre (Nijmegen) that 
are compatible with data from the literature, we found a complete evacuation rate of 
67% in the M&M group versus 54% in the placebo group.[20] We used these rates for 
the calculation of the sample size with an overall significance level of 5%, α = 0.05, 
in combination with a power of 80%, β = 0.20. Based on an improvement of complete 
evacuation rates from 54% to 67%, the trial requires 221 patients in each arm. Considering 
3-4% patients lost-to-follow-up, 230 patients per arm have to be included (total 460). 
Data analysis
Data handling will be done anonymized, with the patient code only available to the 
treating physician and local investigator. Data will initially be analyzed according to 
intention to treat method. The main outcome variable will be assessed by calculating 
success rates in both groups, relative risks, and 95% confidence intervals. A per protocol 
analysis will be performed to evaluate the potential of both strategies, taking into account 
only those cases that were treated according to protocol. Differences between groups will 
be analyzed using the Pearson’s chi-square test or the Fisher’s exact test for categorical 
variables and the Students t-test for continuous variables. Mann-Whitney U test will be 
used for non-normally distributed metric variables and univariate and multivariate logistic 
regression analysis to identify individual factors that are associated with treatment success. 
Economic analysis will be done according to intention to treat principle. Differences in 
total costs between the intervention and control group will be calculated. 
108
CHAPTER 6
Interim analysis and safety monitoring
A data safety monitoring board will be installed, and after including 100 patients in each 
arm, an interim analysis will be done using O’Brien-Fleming stopping rules. This means 
that if M&M treatment (mifepristone followed by misoprostol) is particularly beneficial or 
harmful compared to the control group, the investigators will be able to make a deliberate 
consideration of terminating the study earlier. Local investigators will report (serious) 
adverse events as soon as possible to the sponsor. The sponsor is responsible to report 
serious adverse events (SAE’s) within 15 days to the ethical committee CMO Arnhem- 
Nijmegen.
Discussion
Yearly in the Netherlands, 10.000 women with EPF do not abort spontaneously and do 
undergo medical or surgical treatment, after a minimum of one week of expectant 
management, in order to remove the products of conception from the uterus. Medical 
treatment is a safe and a less expensive alternative to D&C. However, since there is no 
national guideline describing the treatment options for EPF, there is a large practice 
variation between Dutch hospitals.[32]. The current medical treatment with misoprostol 
only after a minimum of one week of expectant management has a complete evacuation 
rate of circa 50%. Thus, 50% of women are still exposed to the risks of complications and 
costs associated with surgery.[2, 13-15]
Medical treatment for EPF may be improved by pre-treatment with mifepristone followed 
by the current treatment with misoprostol alone. The superiority of the combination has 
been demonstrated for termination of vital pregnancy in the first trimester, preparation 
for surgical abortion in the first trimester, termination of vital pregnancy beyond first 
trimester, and induction of labor in case of fetal death after the first trimester.[16, 52, 53] 
Therefore, it is reasonable to consider that also for EPF mifepristone with misoprostol will 
be superior to misoprostol alone. 
A randomized, double blinded placebo-controlled trial is required to deliver the ultimate 
evidence that in EPF the sequential combination of mifepristone with misoprostol is 
superior to the use of misoprostol alone with respect to complete evacuation of products 
of conception, side effects, complications, patient preferences, and costs.
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Mifepristone and misoprostol: M&M
Since the fifties of the last century, surgical intervention (e.g. dilatation and curettage, 
D&C) was the preferred treatment option worldwide in case of early pregnancy failure 
(EPF).[1-3] Although prostaglandins (i.e. misoprostol) were developed in 1973 and the anti- 
progesterone mifepristone in 1980, it took approximately a decade before drug treatment 
regimens were introduced for termination of vital pregnancies or EPF.[4-7] Due to the risks 
of short and long term complications after D&C, medical treatment options will become 
of increasing importance.[8-10] Concurrently, patients have developed a strong preference 
for medical treatment options; they are willing to accept some disadvantages to avoid 
D&C.[11, 12] Also in the Netherlands, health care providers and insurance companies are 
searching for the most cost-effective treatment options and substitution of health care 
from the hospital towards homecare by general practitioners whenever possible.[13, 14] 
In this thesis we focus on a medical treatment option for the evacuation of the products 
of conception in women with EPF: the sequential combination of mifepristone and 
misoprostol (M&M). To provide insight into the hypothesis that M&M is more effective 
than standard misoprostol treatment, we have conducted:
• A systematic review concerning mifepristone in the treatment of EPF, concluding that 
the addition of mifepristone to current misoprostol treatment regimens might increase 
success rates, and thereby reducing the number of surgical interventions. However, 
the evidence from the existing literature is insufficient to draw firm conclusions.[15]
• A single-center retrospective cohort study including patients in the period before and 
after a protocol change (addition of mifepristone to misoprostol), reporting that treatment of 
EPF with M&M was significantly more effective than treatment with misoprostol alone: 
66,8  versus 54,9%.[16]
• A survey among 25 gynecologic centers in the Netherlands (2017), evaluating the use 
and expectations of mifepristone, which reveals a large practice variation regarding 
treatment of patients with EPF. Mifepristone prescription for EPF in the Netherlands 
appears scarce because of lack of sufficient evidence. Physicians are willing to prescribe 
M&M in the future if scientifically evidence-based superior to the use of misoprostol 
alone.[17]
• A two-centered, prospective, randomized, double blinded, placebo controlled pilot 
study, comparing M&M versus misoprostol alone, showing fluent accrual of patients, 
feasibility of the study protocol and measurement of primary and secondary outcomes. 
With this pilot encouraging treatment results in terms of effectiveness (68,4% versus 
40%) and patient satisfaction (84,6% versus 62,6%) are reported, with no serious adverse 
events and significantly less surgical interventions (10,5% versus 50%) after M&M.[18]
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• The composition of the definitive study protocol for a sufficiently powered, multicenter, 
randomized, double blinded and placebo controlled trial to confirm the hypothesis that 
the sequential treatment with M&M is more effective than misoprostol alone, is patient 
preferred, and results in less surgical interventions and significant reduction of 
healthcare costs (www.clinicaltrials.gov, NCT03212352).[19]
Implications for current practice
Terminology
We suggest using the universal term “early pregnancy failure” (EPF), or in Dutch “miskraam”, 
when describing a non-vital pregnancy until 14 weeks of gestation. It should be attempted 
to maintain a uniform definition to prevent confusion between physicians and patients, 
to compare treatment results in the best possible way, to improve implementation of 
research results in daily practice, and to reach similarity in inclusion criteria for future 
research.[20, 21] 
Treatment in case of EPF
Treatment of women with EPF may be improved by protocol-based care preferably 
directed by a nationwide guideline. We recommend starting medical treatment only after 
at least one week of expectant management.[22] Physicians should explain to the patient 
with EPF that expectant management for at least one week leads to complete spontaneous 
miscarriage in approximately 50% of women.[23, 24] After unsuccessful expectant management, 
women then should be thoroughly counseled between medical and surgical treatment 
options.
The first choice after unsuccessful expectant management, after excluding contra-indica-
tions for prostaglandins, should be medical treatment, because it is a safe alternative 
compared to surgical treatment with lower short and long term complication rates and 
costs.[3, 9, 10, 25] Up until now, we advise misoprostol 800μg, followed by a second dose 
of 800μg 24 hours later if no tissue is lost. Ultrasonography should be performed after 1 or 
2 weeks to evaluate whether the gestational sac has been expulsed or is still intra-uterine. 
If the gestational sac has been expulsed, in general, expectant management until six 
weeks after medical treatment is advised, based on the results of the MisoREST-study 
reporting that expectant management is effective in approximately 80% of patients. 
Furthermore, it is safe, and even more important, women have a clear preference for 
expectant management instead of curettage.[26, 27] Curettage is accompanied by the 
risk of complications on short and long term, the incidence of complications varies 
between 0,01% and 1,6%.[8, 9, 28-30] Recent studies also reveal a high prevalence of 
intrauterine adhesions (Asherman syndrome), potentially interfering with subsequent 
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child wish.[10] Moreover, a higher risk of premature delivery in future pregnancies has 
been reported.[9, 31] Therefore, it appears of utmost importance to reduce the need for 
curettage in women with EPF. As reported in our pilot study, M&M treatment may lead to 
significantly less interventions.[18]  
Unfortunately, the current medical treatment with misoprostol alone, after one week of 
expectant management, is successful in approximately 50%. To achieve a substantial 
reduction of surgical interventions it is urgently needed to increase the success rates of 
medical treatment.[2, 16] Besides reduction of complications, effective medical treatment 
is also cost reducing as already shown by Graziosi et al., so, an even more reduction in 
costs is expected when success rates increase.[25] Thereby, approximately 85% of women 
would prefer medical treatment if its complete evacuation rate would reach 80%.[12] 
Concluding, if M&M appears superior to the use of misoprostol alone, M&M may lead to 
less surgical interventions, reduction of complications and costs, and may increase patient 
satisfaction. Although our thesis is already showing very promising results after M&M 
treatment, we must wait for the results of the sufficiently powered randomized, double 
blinded, and placebo-controlled trial (starting second half of 2017, NCT03212352) to draw 
any firm conclusions.[19]
Dutch situation: general practitioner, midwife and early pregnancy unit
In the Netherlands, with a condense medical infrastructure, medical treatment (both 
mifepristone and misoprostol) in case of EPF could be a suitable opportunity for home- 
based care. In the Netherlands, most women primarily visit their local GP or midwife in 
case of a pregnancy.  So, if miscarriage is diagnosed in the first trimester of pregnancy, and 
medical treatment may be necessary, this kind of relatively safe treatment with a very low 
complication rate seems highly suitable to GPs and midwifes to deliver. 
In the Netherlands, physicians may only prescribe medication for termination of a vital 
pregnancy (i.e. abortus provocatus) if they are authorized and licensed to provide such 
treatment. Actually, this is done by doctors working in so-called specific ”abortion clinics”. 
Besides, informed consent is always necessary because of off-label use of misoprostol. At 
this moment, the debate is still going on whether GP’s may prescribe “the abortion pill” i.e. 
mifepristone, in termination of vital pregnancies.[32] If it is allowed for GP’s to prescribe 
mifepristone also in case of EPF, women can visit their GP who knows their complete 
medical record and social context without extra hospital-visit related costs. Of course, for 
future use by GP’s it is required that they are familiar with the contra-indications and 
possible complications of mifepristone and misoprostol use. In case of an emergency, like 
excessive bleeding, the possibility for immediate hospital admission (in a collaborative 
network) is an obligatory condition for substitution of this kind of health care towards GPs. 
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Within this new concept of care, one should also be aware that ultrasonography is 
necessary to confirm the diagnosis of a non-vital pregnancy in utero and its gestational 
age. In the Dutch situation midwifes are, in contrast to GP’s, educated and licensed to 
perform and interpret ultrasonography to diagnose EPF. However, midwives are and 
probably will not be authorized to prescribe mifepristone or misoprostol for the treatment 
of EPF. Therefore, after determining the correct diagnosis, at this moment women are still 
referred to the hospital. This could be changed into referral back to the GP after determining 
diagnosis, ensuring that women are treated by their own GP. In conclusion, the afore-
mentioned EPF treatment concept (see figure 1) may lead to an increase in patient 
satisfaction, improvement of health care quality and substantial reduction of costs (i.e. 
substitution of health care).[33-36]
In England, the care for women during early pregnancy is centralized in more than 200 
specialized “early pregnancy units” (EPU).[37] Treatment of women with EPF takes place 
in these EPUs if available in the nearby area, because the logistical improvements and 
bundling of expertise lead to expert guidance of women by a dedicated team of 
physicians, and improvement of health care quality. Women are guided by physicians who 
also have an extra focus on the differential diagnosis of EPF, for example bleeding in a vital 
pregnancy, extra-uterine pregnancy or pregnancy of unknown location. Also guidance in 
case of recurrent miscarriages can be given by the same dedicated team of physicians. 
In the Netherlands only two EPUs have been opened until now, causing that referral to an 
EPU is not an option for many Dutch women.[38]
Global health: EPF care in low-resource countries
Differences in healthcare between high- (like the Netherlands) and low-resource countries 
are well known. Costs and distance to healthcare providers have major influences on the 
opportunities for primary healthcare. Surgical methods may be scarce and may be even 
more hazardous in low-income countries due to lack of trained staff, lack of material or 
inadequate transportation to centers where surgical procedures are performed. Also 
cultural norms, community beliefs, financial aspects, distance to the hospital, education, 
and lack of knowledge determine whether women seek medical help at all.[39, 40]
In places with limited resources, medical treatment options may be extremely helpful to 
reduce both morbidity and mortality rates.[39, 41] Compared to surgical, medical treatment 
has even more advantages in low than in high-resource countries, for example by its 
low-costs (in the Netherlands 1.02 euro for one misoprostol tablet), easy availability and 
storage at room temperature. A one-stop-shop EPF approach, to determine diagnosis and 
start treatment on the same day, could be very useful. However, if it’s not secured that 
patients return for follow-up, high treatment efficacy is essential. Since the sequential 
combination of mifepristone and misoprostol may lead to higher success rates, reducing 
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Figure 1   Proposed treatment protocol for early pregnancy failure
*  Uncomplicated cases (referral to EPU or local hospital in case of uncertain diagnosis, i.e. extra-uterine 
pregnancy or pregnancy of unknown location)
Intra-uterine
“remnants”
Treatment coordinated by
general practitioner/midwife
(with back-up of local hospital)*   
Treatment coordinated by
gynecologist 
 
 
 
 EPF confirmed by ultrasonography
 Ultrasonography 1-2 weeks after treatment
Complete
evacuation
Gestational sac
intra-uterine
Expectant management for at least one week
Medical treatment
(Mifepristone followed by?) Misoprostol 2x 800µg
Circa 50% spontaneous
complete miscarriage 
Ultrasonography: gestational sac
still intra-uterine, counseling  
Follow up: ultrasonography after 
4 weeks of expectant management
or first spontaneous menstruation 
Referral to gynecologic center:
counseling D&C
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the need for additional surgical intervention, M&M in case of EPF could be of utmost 
importance in low-resource countries. Certainly, since the costs of mifepristone are decreasing 
drastically (current costs in the Netherlands 11.66 euro per tablet), this treatment option 
may have significant impact on health care safety and costs in low-resource countries.[42]
Topics for future research
Conception of a nationwide guideline for EPF
A sufficiently powered, multicenter, randomized, double blinded, and placebo-controlled 
trial will start at the end of 2017, funded by “Innovatiefonds Zorgverzekeraars”, Canisius- 
Wilhelmina Hospital and Radboud University Medical Centre (NCT03212352). Definitely, 
a robust RCT is necessary to obtain evidence to confirm the hypothesis that sequential 
treatment with mifepristone and misoprostol is superior to the use of misoprostol alone in 
terms of effectiveness (reduction of surgical interventions), risks of complications, patient 
satisfaction and preference, and costs. 
After establishing the most optimal treatment regimen, a national guideline should be 
developed as soon as possible to minimize the current practice variation in het Netherlands. 
[17, 43] Besides describing the specific diagnostic and treatment regimen in case of EPF, 
recommendations must be made where patients are treated. To our opinion, women may 
preferably be treated by their own GP and/or midwife backed up by the local hospital, 
united in a collaborative network (figure 1). This guideline should be developed by the 
NVOG (the Dutch association for Obstetrics and Gynecology) in close collaboration with 
the NHG (the Dutch College of General Practitioners) and KNOV (Royal Dutch association of 
Midwives). Also, if our hypothesis is confirmed by the above-mentioned trial, the recom-
mendations made by the World Health Organization regarding the medical treatment of 
EPF should be adjusted to M&M.
Development of decision aid
Miscarriage may lead to higher levels of anxiety, depression and post-traumatic stress.[44, 
45] The development of a decision aid describing expectant, medical, and (preferably 
only if strictly necessary) surgical treatment options, could be very helpful for both patient 
and physician in a shared decision making process to reduce this stress. Patient preferences 
should be taken seriously during the process of establishing the most optimal treatment 
regimen. Especially the woman’s own opinions concerning the timing of examination 
and follow-up after treatment is unknown yet. After studying women’s preferences and 
considerations, a thorough and evidence based decision aid can be created, followed by 
evaluation of the implementation and its effects in clinical practice. 
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Individualized medicine 
Future research should furthermore focus on a risk model and risk factors, on the basis of 
a multivariate analysis. Predicting successful medical treatment in EPF, i.e. to estimate a 
woman’s individual chance of reaching complete evacuation, will contribute to the correct 
selection of patients for medical treatment and minimize the risk of complications.[46-49] 
Recent reports mention that medical treatment may be more effective in case of non- 
Hispanic ethnicity, null parity, non-obesity, high hCG levels (> 4000 mIU/mL), and high 
progesterone levels (> 10 nmol/); however, further research is necessary.[48, 49]
Improvement of outcome measurement
With regards to the follow-up of women receiving medical treatment: ultrasonography 
seems to be of limited value in predicting the presence of intrauterine remnants shortly 
(1-2 weeks) after medical treatment. Previous studies do not provide any clear evidence 
which endometrial thickness corresponds best to the presence of intrauterine pregnancy 
remnants.[27, 50, 51] Further evaluation is needed to see which diagnostic tool is best in 
determining retained products of conception, for example: clinical signs and symptoms, 
vaginal examination of the cervix (open or closed ostium internum), (Doppler) ultrasonog-
raphy, blood tests (hCG) or any combination of these aspects. Also the time period to 
determine treatment success should be studied. 
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Summary
In chapter 1 the background, rationale and aims of this thesis are described. In the Netherlands, 
approximately 10,000 women per year undergo some form of treatment in case of early 
pregnancy failure (EPF). Dilatation and curettage (D&C), although resulting in a high 
effectiveness of 95-100%, is accompanied by the risk of complications. A non-invasive, 
medical treatment is misoprostol, used for EPF since approximately 1985. Unfortunately, 
after one week of expectant management, only in 50-60% of the cases a complete miscarriage 
is achieved. A new medical treatment option may be pretreatment with mifepristone 
followed by misoprostol (M&M). This combination has already been proven superior to 
treatment with misoprostol alone for other indications of termination of pregnancy. In this 
thesis more insight is provided into the effectiveness of M&M in case of EPF.
A systematic review of the existing literature is described in chapter 2, evaluating the 
added value of mifepristone in women with EPF. Electronic databases were searched and 
all relevant clinical studies reporting on the added value of mifepristone to current 
nonsurgical treatment regimens were included. Data of sixteen studies (five randomized 
and eleven non-randomized trials) were extracted using a data extraction sheet (based on 
the Cochrane Consumers and Communication Review Group’s data extraction template). 
The methodological quality was assessed using the Cochrane Collaboration Risk of Bias 
tool. The available evidence revealed that medical treatment appears to be a safe 
alternative to surgical evacuation, leading to savings and a reduced number of (serious) 
complications. Success rates of M&M in case of EPF varied between 52% and 95%. 
Unfortunately, large heterogeneity existed in treatment regimens between studies. 
Therefore, up until now the existing evidence appears insufficient to draw firm conclusions 
about the added value of mifepristone to misoprostol in case of EPF. 
Chapter 3 describes a retrospective study, which has been performed at the Radboud 
University Medical Center. Between 2008 and 2013, patients were already pretreated with 
mifepristone (200 – 600mg) followed by misoprostol (400 – 800μg). A total number of 
301 patients with EPF between 6-14 weeks were included. 199 patients received M&M, 
and 102 patients received misoprostol alone. Complete expulsion of the products of 
conception in women treated with M&M was 67%; in women treated with misoprostol 
alone a success rate of 54% was reported (p = 0.045). M&M treatment appeared more 
effective in case of EPF compared to misoprostol alone, however, these findings have to be 
confirmed by a sufficiently powered, multicenter, randomized, and placebo-controlled trial.
In chapter 4 the current and future expectations of M&M in case of EPF are evaluated, 
using a digital questionnaire sent to a representative sample of gynecologic centers in the 
Netherlands (25/79 = 32%). Questions were asked regarding the presence of a local 
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protocol, the current prescription of medical treatment, and the use and future 
expectations of mifepristone in case of EPF. We also focused on follow-up procedures 
after medical treatment since literature concerning the most optimal follow-up period 
and diagnostic tool is lacking. A local protocol was present in 88% with a significant 
difference between academic and teaching (100%) versus non-teaching centers (57,1%). 
The first choice of treatment was medical in 54,5% of centers. Only 20% of the respondents 
“always” or “usually” prescribed M&M in case of EPF, estimating the complete evacuation 
rate between 50% and 100% with similar side effects compared to treatment with 
misoprostol alone. The most given reason for not prescribing mifepristone for EPF was 
lack of sufficient evidence of effectiveness. An average increase in success rate of 21,7% 
was required to prescribe mifepristone in the future for EPF. Treatment effect was usually 
assessed by clinical signs and ultrasonography; using 4 – 15 millimeters cut-off points for 
total endometrial thickness to diagnose complete evacuation. If a complete evacuation 
was not achieved by the initial medical treatment, expectant management was proposed 
just as often as direct surgical intervention (i.e. dilatation and curettage or hysteroscopy). 
Concluding, although in most centers in the Netherlands a local protocol is present, there 
is still a large practice variation in the treatment of EPF. The use of M&M in EPF is not 
common practice, due to the lack of sufficient evidence. However, a scientifically proven 
increase in effectiveness may lead to prescription of M&M in more centers in the future.
In chapter 5 a two-centered, prospective, two-armed, randomized, double blinded, 
placebo- controlled pilot study is described evaluating M&M treatment in case of EPF, and 
to test feasibility and recruitment of the proposed study protocol. In the Radboud 
University Medical Centre and Canisius-Wilhelmina Hospital in Nijmegen (the Netherlands), 
women with a diagnosis of EPF between 6 and 14 weeks of gestation were included 
after at least one week of expectant management. 40 women were included; on day one 
20 women were pre-treated with 600mg mifepristone (orally) and 20 women received 
placebo pretreatment. In both groups this was followed by misoprostol 800μg (oral) on 
day 3, and if necessary on day 4. A transvaginal ultrasonography six to nine days after 
treatment determined the primary outcome. Successful treatment was defined by an 
endometrial thickness < 15mm or no evidence of retained products of conception using 
only the allocated therapy by randomization. Complete evacuation was achieved in 68,4% 
of women in the M&M group versus 40% of women in the placebo group. The need for 
surgical intervention, was significantly lower in the M&M group as compared to the 
placebo group: 10,5% versus 50% respectively. No serious adverse events were reported in 
either group. Quality of life was similar in both groups. The majority of women, 84,6%, 
in the M&M group versus 62,6% of women in the placebo group, would choose medical 
treatment again if necessary. In the M&M group 92,3% and in the placebo group 75% of 
women would recommend medical treatment to a friend in case of EPF. Feasibility of the 
study protocol was confirmed and recruitment of patients was as expected. 
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Chapter 6 describes the definitive study protocol with a sufficient number of patients to 
compare addition of mifepristone (M&M) to the standard treatment with misoprostol 
alone in terms of complete evacuation of products of conception from the uterus, 
patient satisfaction, complications, side effects and cost-effectiveness (NL 62449.091.17, 
NCT03212352). Due to our data from the retrospective and pilot study we were able to 
optimize the study protocol; the multicenter trial will start second half of 2017.
A general discussion is presented in chapter 7, evaluating the findings of this thesis. 
Implications for current practice and recommendations of future research are made to 
improve the treatment of women with early pregnancy failure including the substation of 
health care towards general practitioners and midwifes. 
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Samenvatting
In hoofdstuk 1 worden de achtergrond en doelstellingen van dit proefschrift beschreven. 
In Nederland ondergaan ongeveer 10.000 vrouwen per jaar een behandeling vanwege 
een miskraam. (Zuig)curettage onder enige vorm van anesthesie in een kliniek of zieken- 
huis gaat ondanks een hoog slagingspercentage van 95-100%, gepaard met een risico 
op korte en lange termijn complicaties. Een inmiddels veel toegepaste niet-operatieve, 
medicamenteuze behandeling bestaat uit het gebruik van misoprostol tabletten. Helaas 
wordt, na ruim 1 week afwachten op een spontane miskraam, met misoprostol slechts 
in 50-60% van de vrouwen een volledige miskraam bereikt. Een nieuwe optie is de 
 combinatiebehandeling: voorbehandeling met mifepriston gevolgd door misoprostol 
tabletten (M&M). Deze combinatie blijkt bewezen superieur in vergelijking met de behandeling 
met alleen misoprostol voor andere indicaties voor het beëindigen van zwangerschappen 
zoals bij abortus provocatus. Dit proefschrift verschaft verder inzicht in de effectiviteit van 
M&M bij vrouwen met een miskraam.
Een systematisch literatuuroverzicht wordt beschreven in hoofdstuk 2 waarin de toegevoegde 
waarde van mifepriston bij vrouwen met een miskraam wordt geëvalueerd. Diverse 
elektronische databanken werden systematisch doorzocht en studies, welke rapporteren 
over de toegevoegde waarde van mifepriston aan huidige niet-chirurgische behandel-
methoden, werden geanalyseerd. Gegevens van zestien studies (vijf gerandomiseerde en 
elf niet-gerandomiseerde studies) werden geëxtraheerd met behulp van een data- 
extractie sheet (op basis van de “Cochrane Consumers and Communication Review 
Group’s data extraction template”). De methodologische kwaliteit werd beoordeeld met 
behulp van de “Cochrane Collaboration Risk of Bias tool”. De slagingspercentages van de 
behandeling met mifepriston én misoprostol varieerden tussen 52% en 95%. Helaas 
bestond er een grote diversiteit in de behandelschema’s tussen deze studies. Concluderend 
is er tot op heden nog onvoldoende wetenschappelijk bewijs omtrent de toegevoegde 
waarde van mifepriston aan misoprostol bij de behandeling van vrouwen met een 
miskraam.
Hoofdstuk 3 beschrijft een retrospectieve studie welke is uitgevoerd in het Radboud 
Universitair Medisch Centrum te Nijmegen. Tussen 2008 en 2013 werden aldaar reeds 
patiënten met miskraam behandeld met de combinatie van mifepriston voorbehandeling 
(200 - 600mg) gevolgd door misoprostol (400 - 800μg). Een totaal aantal van 301 patiënten 
met een miskraam werd geïncludeerd bij een zwangerschapsduur tussen 6 en 14 weken. 
199 patiënten kregen de M&M combinatie voorgeschreven en 102 patiënten kregen 
alleen misoprostol. Een succespercentage (d.w.z. een complete miskraam) van 67% in 
de M&M groep versus 54% in de groep die alleen misoprostol kreeg resulteerde in een 
significant verschil (p = 0.045).
136
CHAPTER 8
In hoofdstuk 4 worden de huidige ervaringen en toekomstige verwachtingen van M&M 
bij vrouwen met een miskraam geëvalueerd m.b.v. een digitale enquête verzonden naar 
een representatieve sample van gynaecologische centra in Nederland (25/79 = 32%). 
In deze elektronische enquête zijn vragen omtrent de aanwezigheid van een lokaal 
protocol, het voorschrijven van een medicamenteuze behandeling, het huidige gebruik 
en de toekomstige verwachtingen van mifepriston bij vrouwen met een miskraam 
gesteld. Daarnaast lag de focus van enkele vragen op de evaluatie/follow-up procedure 
na medicamenteuze behandeling. Een lokaal protocol was aanwezig in 88% van de 
centra, met een significant verschil tussen academische en perifere opleidingsklinieken 
(100%) versus perifere niet-opleidingsklinieken (57,1%). De eerste keus van behandeling 
was medicamenteus in 54,5%. Slechts 20% van de respondenten schreven M&M “altijd” of 
“meestal” voor aan vrouwen met een miskraam, waarbij het slagingspercentage tussen 
50% en 100% werd geschat zonder toename van het aantal bijwerkingen. De meest gegeven 
reden om mifepriston (nog) niet voor te schrijven was gebrek aan wetenschappelijk 
bewijs voor deze indicatie. Een gemiddelde toename van het slagingspercentage van 
21,7% was gewenst om mifepriston in de toekomst wel voor te voorschrijven in geval van 
een miskraam. Het effect van de behandeling werd meestal beoordeeld m.b.v. echoscopie in 
combinatie met klinische symptomen (64%). De echoscopisch vast te stellen afkapwaarde 
van de totale endometrium (baarmoederslijmvlies) dikte waarbij men een complete 
miskraam diagnosticeerde varieert tussen 4 en 15 millimeter. Als er sprake was van een 
zodanig geconstateerde ”incomplete” miskraam, werd een expectatief beleid in de 
diverse klinieken even vaak voorgesteld als een chirurgische interventie (curettage). 
Concluderend, alhoewel er in de meeste centra in Nederland een lokaal protocol aanwezig 
is, bestaat er nog steeds een grote praktijkvariatie in de behandeling van vrouwen met 
een miskraam in NL. Het gebruik van M&M is (nog) niet gebruikelijk voor deze indicatie 
door een reeds eerder vermeld gebrek aan wetenschappelijk bewijs. Echter, een bewezen 
toename van de effectiviteit kan ervoor zorgen dat gynaecologen M&M in de toekomst 
wel gaan voorschrijven.
Een prospectief, gerandomiseerd, dubbelblind, placebo-gecontroleerd pilotstudie werd 
uitgevoerd in twee centra om M&M-behandeling bij vrouwen met een miskraam weten-
schappelijk te evalueren en om de haalbaarheid van het voorgestelde definitieve 
studieprotocol te toetsen (hoofdstuk 5). Vrouwen met miskraam tussen 6 en 14 weken 
zwangerschap werden na minstens één week expectatief beleid geïncludeerd in het 
Radboud Universitair Medisch Centrum en het Canisius-Wilhelmina Ziekenhuis te Nijmegen. 
In totaal werden 40 vrouwen geïncludeerd, 20 vrouwen werden behandeld met 600mg 
mifepriston (oraal), 20 vrouwen kregen een placebo tablet. In beide groepen werd dit 
gevolgd door de medicamenteuze behandeling bestaande uit misoprostol 800μg oraal. 
Een transvaginale echoscopie zes tot negen dagen na behandeling, werd verricht om de 
primaire uitkomstmaat vast te stellen. Een succesvolle behandeling was gedefinieerd als 
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een totale endometrium (baarmoederslijmvlies) dikte minder dan 15mm zonder dat de 
vrouw een andere behandeling naast de toegewezen behandeling door randomisatie 
had ondergaan. Een complete miskraam werd bereikt in 68,4% van de vrouwen in de 
M&M groep versus 40% van de vrouwen in de placebo groep. De noodzaak voor een 
aanvullende chirurgische interventie (curettage) was significant lager in de M&M groep in 
vergelijking met de placebogroep: respectievelijk 10,5% en 50%. Er werden geen ernstige 
bijwerkingen gerapporteerd en de gemeten kwaliteit van het leven was vergelijkbaar in 
beide groepen. De meerderheid van de vrouwen, 84,6%, in de M&M-groep versus 62,6% 
van de vrouwen in de placebogroep, zou indien noodzakelijk bij een volgende miskraam 
weer dezelfde behandeling verkiezen. In de M&M groep zou 92,3% en in de placebogroep 
75% van de vrouwen deze medicamenteuze behandeling aanbevelen aan een vriendin. 
De pilotstudie, waarbij haalbaarheid en de inclusie van patiënten was zoals verwacht, 
leidde tot enkele aanpassingen in het definitieve protocol.
Hoofdstuk 6 beschrijft het definitieve multicenter studieprotocol (NL 62449.091.17) waarin 
de toevoeging van mifepriston aan de behandeling met misoprostol wordt vergeleken 
voor wat betreft effectiviteit (= primaire uitkomstmaat), patiënttevredenheid, complicaties, 
bijwerkingen en kosteneffectiviteit. Op basis van gegevens en resultaten verkregen uit de 
in dit proefschrift beschreven (retrospectieve- en pilot) studies, is het studieprotocol ge-
optimaliseerd, hetgeen najaar 2017 zal leiden tot start van deze zogenaamde multicenter 
M&M trial.
In hoofdstuk 7 wordt een algemene discussie beschreven, waarbij de bevindingen van dit 
proefschrift worden geëvalueerd in het licht van de huidige behandelmogelijkheden van 
vrouwen met een miskraam. Implicaties voor de huidige praktijk en aanbevelingen voor 
toekomstig onderzoek worden gedaan om de behandeling verder kwalitatief en kosten-
effectief te verbeteren, waarbij onzes inziens een transitie van tweede naar eerstelijns zorg 
is aangewezen.
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Abbreviations
ACOG American College of Obstetricians and Gynecologists
AG  Anembryonic gestation
APD  Anterior-posterior (double) layer endometrial diameter
CRF  Case report form
CSQ  Client satisfaction Questionnaire
D&C  Dilatation and curettage
EFD  Embryonic or fetal demise
EPF  Early pregnancy failure
EPU  Early pregnancy unit
EuroQol-VAS EuroQol visual analogue scale
FIGO  International Federation of Gynecology and Obstetrics
GP  General practitioner
GS  Gestational sac
M&M  mifepristone and misoprostol
NVOG Nederlandse Vereniging voor Obstetrie & Gynaecologie
RCOG Royal College of Obstetricians and Gynecologists
SF-36  Short Form 36
US  Ultrasound
WHO  World Health Organization
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Questionnaires
A Dutch survey among gynecologists (chapter 4) 
De medicamenteuze behandeling van vrouwen met een miskraam is vooralsnog niet 
optimaal. Hierdoor worden nog veel curettages verricht met het bijkomende risico op 
complicaties. Deze enquête is bedoeld om meer inzicht te krijgen in het gebruik van 
mife-priston in Nederland. Schrijft u weleens mifepriston voor? 
1. Wat is uw geslacht?
 o Man
 o Vrouw
2. Wat is uw leeftijd?
 …………
3. Hoeveel jaar bent u gynaecoloog?
 …………
4. In welke kliniek bent u werkzaam? 
 o Academisch centrum
 o Perifeer opleidingsziekenhuis
 o Perifeer ziekenhuis
5. De naam van de kliniek waar u werkzaam bent is:
 …………
Lokaal protocol
6. Is er in uw ziekenhuis een lokaal protocol miskraambehandeling?
 o Ja
 o Nee
7. Wat is de eerste keus behandeling bij een miskraam (na een expectatieve periode) 
volgens het lokale protocol van uw ziekenhuis?
 o Medicamenteus
 o Chirurgie
 o Voorkeur van patiënte en/of arts
 o Er is geen lokaal protocol
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Lokaal protocol / afspraken
Alle vragen gaan over de behandeling van vrouwen met een miskraam zónder lichamelijke 
klachten zoals buikpijn of bloedverlies.
8. Zijn er in uw ziekenhuis mondelinge afspraken omtrent de eerste keus van 
behandeling?
 o Ja, medicamenteus
 o Ja, chirurgie
 o Ja, voorkeur van patiënte en/of arts
 o Nee 
Keuze behandeling
Alle vragen gaan over de behandeling van vrouwen met een miskraam zónder lichamelijke 
klachten zoals buikpijn of bloedverlies.
9. Start u de behandeling na minstens één week expectatief beleid? Deze week 
afwachten kan ook in de eerste lijn hebben plaats gevonden.
 o Altijd
 o Meestal wel
 o Alleen op indicatie
 o Nooit
10. Schrijft u weleens een medicamenteuze behandeling voor?
 o Ja 
 o Nee 
11. Vanwege welke reden bespreekt u geen medicamenteuze behandeling? Meerdere 
antwoorden zijn mogelijk.
 o Lage effectiviteit 
 o Langer behandeltraject 
 o Staat niet in lokaal protocol beschreven c.q. is niet volgens lokale afspraken
 o Medico-legaal: i.v.m. off-label gebruik misoprostol en/of mifepriston
 o Ik bespreek wel een medicamenteuze behandeling
Mifepriston
Alle vragen gaan over de behandeling van vrouwen met een miskraam zónder lichamelijke 
klachten zoals buikpijn of bloedverlies.
12. Wordt mifepriston in uw lokale protocol beschreven?
 o Ja
 o Nee, dit wordt niet beschreven
 o Nee, er is geen lokaal protocol
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13. Schrijft u mifepriston voor?
 o Altijd 
 o Meestal wel
 o Alleen op indicatie
 o Nooit
14. Waarom schrijft u geen mifepriston voor? Meerdere antwoorden zijn mogelijk.
 o Ontbreken van wetenschappelijk bewijs
 o Medico-legaal: is hier niet voor geregistreerd
 o Kosten
 o Bijwerkingen
 o Ik schrijf wel mifepriston voor
 o Anders, namelijk …
15.  Welke dosering mifepriston schrijft u voor?
 o 200mg 
 o 400mg
 o 600mg
 o Anders, namelijk …
16. De bijsluiter beschrijft dat mifepriston onder toezicht van een arts of één van diens 
medewerkers moet worden ingenomen. Hoe is de inname in uw ziekenhuis?
 o Onder toezicht van een arts of andere medewerker 
 o Inname vind niet onder toezicht plaats maar wel in het ziekenhuis
 o Inname vind thuis plaats
17. Welk tijdsinterval hanteert u tussen inname van mifepriston en start van 
misoprostol? 
 …………
18. Kunt u het effect inschatten van de behandeling met mifepriston en misoprostol? 
Het aantal complete miskramen ligt tussen:
 o 0 – 25 % 
 o 25 – 50 % 
 o 50 – 75 % 
 o 75 – 100%
19. Kunt u een inschatting maken van de frequentie van bijwerkingen bij het gebruik 
van mifepriston?
 o Meer dan bij de behandeling met alleen misoprostol 
 o Evenveel als bij de behandeling met alleen misoprostol
 o Minder dan bij de behandeling met alleen misoprostol
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Kosten
20. Een medicamenteuze behandeling met alleen misoprostol kost ongeveer 2 euro. 
Mifepriston is, afhankelijk van de dosering, circa 12 tot 36 euro. Bij welke effectiviteit 
zou u besluiten mifepriston wel voor te schrijven? Ga hierbij uit van een effectiviteit 
van een behandeling met alleen misoprostol van 55%. Bij een totale effectiviteit 
(in procent) van: ………
Follow-up
21. Wanneer spreekt u een eerste controle na een medicamenteuze behandeling af? 
 o Na 1 week
 o Na 6 weken
 o Na de eerstvolgende menstruatie
 o Niet, alleen bij klachten
 o Anders, namelijk…
22. Hoe bepaald u of de miskraam compleet is?
 o Echoscopie
 o Klinisch beeld i.c.m. echoscopie
 o Alleen o.b.v. klinisch beeld
 o Anders, namelijk… 
23. Hoe beoordeeld u bij echoscopie of de uterus leeg is?
 o “Op het oog”: beeld wel/niet passend bij een rest  
 o Meting van totale endometrium dikte (TED)
 o Er wordt geen echo gemaakt
 o Anders, namelijk… 
24. Vanaf welke totale endometrium dikte spreekt u van een complete miskraam?
 …………
25. Wat is uw beleidsvoorstel in geval van een rest? Ga hierbij uit van een hemodynamisch 
stabiele patiënt zonder tekenen van infectie.
 o Expectatief 
 o Curettage
 o Curettage onder echogeleide 
 o Hysteroscopie
 o Nogmaals behandeling met misoprostol
 o Anders, namelijk…
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26. Indien u een afwachtend beleid afspreekt, wanneer ziet u patiënte weer terug voor 
controle?
 o Na de eerstvolgende menstruatie
 o Niet, alleen bij klachten
 o Anders, namelijk…
Wij willen u hartelijk bedanken voor het invullen van deze vragenlijst. 
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Quality of life and patient satisfaction: a pilot study (chapter 5) 
U heeft toestemming gegeven om deel te nemen aan de M&M-studie. In het kader 
van deze studie willen we graag in kaart brengen hoe uw gezondheidstoestand en 
tevredenheid op dit moment is. Door het beantwoorden van deze vragenlijst draagt u 
eraan bij dat we de zorg rondom miskramen kunnen verbeteren. Daarom vragen we u om 
de vragenlijst in te vullen, dit zal u enkele minuten van uw tijd kosten. U wordt verzocht 
alle vragen te beantwoorden. Als vragen niet helemaal duidelijk zijn kunt u contact opnemen 
met uw ziekenhuis. Deze vragenlijst zal strikt vertrouwelijk en anoniem verwerkt worden.
Short-form 36
In deze vragenlijst wordt naar uw gezondheid gevraagd. Wilt u alstublieft elke vraag 
beantwoorden door het juiste antwoord aan te klikken? Wanneer u twijfelt, probeer dan 
het antwoord te geven dat het meest van toepassing is. 
1.  Wat vindt u, over het algemeen genomen, van uw gezondheid?
 o uitstekend
 o zeer goed
 o goed
 o matig
 o slecht
2. In vergelijking met een jaar geleden, hoe zou u nu uw gezondheid beoordelen?
 o veel beter dan een jaar geleden 
 o iets beter dan een jaar geleden 
 o ongeveer hetzelfde als een jaar geleden 
 o iets slechter dan een jaar geleden 
 o veel slechter dan een jaar geleden 
3.  De volgende vragen gaan over dagelijkse bezigheden. Wordt u door uw gezondheid 
op dit moment beperkt bij deze bezigheden? Zo ja, in welke mate?
Ja, ernstig 
beperkt
Ja, een 
beetje 
beperkt
Nee, 
helemaal 
niet 
beperkt
Forse inspanning zoals hardlopen,  
zware voorwerpen tillen, inspannend sporten 
o o o
Matige inspanning zoals het verplaatsen van  
een tafel, stofzuigen, fietsen 
o o o
Tillen of boodschappen dragen o o o
Een paar trappen oplopen o o o
Eén trap oplopen o o o
Buigen, knielen of bukken o o o
Meer dan een kilometer lopen o o o
Een halve kilometer lopen o o o
Honderd meter lopen o o o
Uzelf wassen of aankleden o o o
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4.  Had u, ten gevolge van uw lichamelijke gezondheid de afgelopen 4 weken één van 
de volgende problemen bij uw werk of andere dagelijkse bezigheden? Vink aan wat 
van toepassing is, meerdere antwoorden zijn mogelijk.
 o Ja, u heeft minder tijd kunnen besteden aan werk of andere bezigheden 
 o Ja, u heeft minder bereikt dan u zou willen 
 o Ja, u was beperkt in het soort werk of het soort bezigheden
 o  Ja, u had moeite met het werk of andere bezigheden (het kostte u bijvoorbeeld 
extra inspanning)
 o Nee
5.  Had u, ten gevolge van een emotioneel probleem (bijvoorbeeld doordat u zich depressief 
of angstig voelde), de afgelopen 4 weken één van de volgende problemen bij uw werk of 
andere dagelijkse bezigheden? Vink aan wat van toepassing is, meerdere antwoorden 
zijn mogelijk.
 o Ja, u heeft minder tijd kunnen besteden aan werk of andere bezigheden
 o Ja, u heeft minder bereikt dan u zou willen
 o  Ja, u heeft het werk of andere bezigheden niet zo zorgvuldig gedaan als u 
gewend bent
 o Nee
6.  In hoeverre heeft uw lichamelijke gezondheid of hebben uw emotionele 
problemen u de afgelopen 4 weken belemmerd in uw normale sociale bezigheden 
met gezin, vrienden, buren of anderen?
 o helemaal niet
 o enigszins
 o nogal
 o veel
 o heel erg veel 
7.  Hoeveel pijn had u de afgelopen 4 weken?
 o geen
 o heel licht
 o licht
 o nogal
 o ernstig
 o heel ernstig
8.  In welke mate heeft pijn u de afgelopen 4 weken belemmerd bij uw normale 
werkzaamheden (zowel werk buitenshuis als huishoudelijk werk)?
 o helemaal niet
 o enigszins
 o nogal
 o veel
 o heel erg veel
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De volgende vragen gaan over hoe u zich de afgelopen 4 weken heeft gevoeld. Wilt u bij 
elke vraag het antwoord aankruisen dat het beste aansluit bij hoe U zich heeft gevoeld?
9.  Hoe vaak gedurende de afgelopen 4 weken:
Voortdurend Meestal Vaak Soms Zelden Nooit
Voelde u zich levenslustig o o o o o o
Voelde u zich erg zenuwachtig o o o o o o
Zat u zo erg in de put dat niets u 
kon opvrolijken 
o o o o o o
Voelde u zich kalm en rustig o o o o o o
Voelde u zich erg energiek o o o o o o
Voelde u zich neerslachtig en 
somber 
o o o o o o
Voelde u zich uitgeblust o o o o o o
Voelde u zich gelukkig o o o o o o
Voelde u zich moe o o o o o o
10.  Hoe vaak hebben uw lichamelijke gezondheid of emotionele problemen gedurende 
de afgelopen 4 weken uw sociale activiteiten (zoals bezoek aan vrienden of naaste 
familieleden) belemmerd?
o voortdurend 
o meestal 
o soms 
o zelden 
o nooit 
11.  Wilt u bij de volgende vragen het antwoord kiezen dat het beste weergeeft hoe juist 
of onjuist u elke uitspraak voor uzelf vindt?
Volkomen 
juist
Groten-deels 
juist
Weet ik 
niet
Groten-
deels 
onjuist
Volkomen 
onjuist
Ik lijk gemakkelijker ziek te worden 
dan andere mensen
o o o o o
Ik ben net zo gezond als andere 
mensen die ik ken
o o o o o
Ik verwacht dat mijn gezondheid  
achteruit zal gaan
o o o o o
Mijn gezondheid is uitstekend o o o o o
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EuroQol-VAS
Om mensen te helpen bij het aangeven hoe goed of hoe slecht een gezondheidstoestand is, 
hebben we een meetschaal (te vergelijken met een thermometer) gemaakt. Op de meet- 
schaal hiernaast betekent “100” de beste gezondheidstoestand die u zich kunt voorstellen, 
en “0” de slechtste gezondheidstoestand die u zich kunt voorstellen. Geef hiernaast aan 
welk punt op de meetschaal volgens u aangeeft hoe goed of hoe slecht uw gezondheids-
toestand vandaag is. Uw gezondheidstoestand vandaag is.
|--------------------------|--------------------------|--------------------------|--------------------------|
0 25 50 75 100
Client Satisfaction Questionnaire 
Met deze vragenlijst kunnen we de behandeling evalueren en verder verbeteren. We zijn 
geïnteresseerd in uw oprechte mening, positief of negatief, over de behandeling die u 
hebt ontvangen. Gelieve alle vragen te beantwoorden.
1)  Hoe zou je de kwaliteit van de behandeling die je kreeg beoordelen?
 o Uitstekend
 o Goed
 o Redelijk
 o Slecht
2)  Kreeg je de soort behandeling die je wou?
 o Neen, zeker niet
 o Neen, niet echt
 o  Ja, over het algemeen wel
 o Ja, ongetwijfeld
3)  In welke mate kwam de behandeling aan jouw noden tegemoet?
 o Al mijn behoeften zijn vervuld
 o De meeste van mijn behoeften zijn vervuld
 o Slechts een klein deel van mijn behoeften is vervuld
 o Geen van mijn behoeften zijn vervuld
4)   Als een vriend gelijkaardige hulp nodig heeft, zou je hem of haar deze behandeling 
aanraden?
 o Zeker niet
 o Niet echt
 o Over het algemeen wel
 o Ongetwijfeld
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5) Hoe tevreden ben je met de behandeling die je hebt gekregen?
 o Redelijk ontevreden
 o Onverschillig/licht ontevreden
 o Grotendeels tevreden
 o Heel tevreden
6)   Heeft de behandeling die je kreeg je geholpen om effectiever om te gaan met je 
problemen?
 o Ja, ze hielpen enorm
 o Ja, ze hielpen een beetje
 o Neen, ze hielpen echt niet
 o Neen, ze maakten het erger
7)  In het algemeen, hoe tevreden ben je met de behandeling die je hebt gekregen?
 o Heel tevreden
 o Grotendeels tevreden
 o Onverschillig/licht ontevreden
 o Redelijk ontevreden
8)  Als je opnieuw hulp zou zoeken, zou je opnieuw kiezen voor deze behandeling?
 o Zeker niet
 o Niet echt
 o Over het algemeen wel
 o Ongetwijfeld
Wij willen u hartelijk bedanken voor het invullen van deze vragenlijst. Nogmaals wijzen wij 
u erop dat deze gegevens strikt vertrouwelijk en anoniem worden verwerkt.
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DATA MANAGEMENT
Research data management according to the FAIR principles
Handling of all study data concerning this thesis “Mifepristone in the management of early 
pregnancy failure” is the responsibility of the coordinating investigator and the Radboud 
University Medical Center Nijmegen, the Netherlands.
The pilot study protocol is open, free and universally accessible at:
1) http://toetsingonline.nl (NL 57892.091.16)
2) http://www.trialregister.nl (NTR 6109)
Data was retrieved from paper and electronic patient records, and directly entered into a 
validated digital database (Castor EDC). Data was organized under anonymous coding 
(consecutively assigned study number). The data was stored apart from the person’s 
identifying information. Digital questionnaires were sent using Castor EDC and directly 
stored in this database. During the clinical trial, a sealed envelope containing the code list 
was locked in a GCP-compliant cabinet at the Clinical Trials Unit of Radboudumc (route 
864, AKF-number 1830). 
The validated digital data management system Castor EDC was used to collect and store 
all (meta)data. (Meta)data are stored on secure Castor servers as well as on the secure 
Radboudumc computer network.
Anonymous data was analyzed using SPSS version 24.0. A list containing the person’s 
identifying information was stored in a GCP-compliant cabinet. The data and analysis files, 
as well ass the code list, were archived after completion of the trial on a locked folder of 
the secure Radboudumc computer network. 
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Dankwoord
Eindelijk is het einde van mijn onderzoek in zicht, waarmee ik niet alleen een proefschrift 
maar ook een ander doel heb bereikt: een opleidingsplek tot gynaecoloog! Zonder de hulp, 
steun en aanmoedigingen van vele mensen om mij heen was dit nooit gelukt, bedankt!
Allereerst wil ik alle vrouwen bedanken die hebben deelgenomen aan de pilotstudie, 
bedankt dat jullie bereid waren om tabletten te slikken zonder te weten wat erin zat, 
en een dagboek en meerdere vragenlijsten hebben ingevuld. Dankzij jullie bijdrage aan 
onze studie kunnen we de behandeling van vrouwen met een miskraam in de toekomst 
optimaliseren. Daarnaast dank aan Exelgyn voor het aanleveren van de studiemedicatie en de 
financiële ondersteuning. Ook alle artsen, verloskundigen, research verpleegkundigen, dokters-
assistenten, apothekers en secretaresses van het CWZ en RUMC wil ik hartelijk danken 
voor hun inzet bij het uitvoeren van de M&M studie. Zonder jullie was het niet gelukt!
Prof. dr. F.P.H.A. Vandenbussche, beste Frank, hartelijk dank voor jouw inzet en eerlijkheid, 
je kritische blik op al mijn artikelen en het feit dat je altijd laagdrempelig bereikbaar was. 
Heel wat uren hebben we samen zitten werken aan de teksten; vooral op de door mij 
gebruikte Engelse tijdsvormen was altijd iets aan te merken. Jouw positieve instelling en 
vertrouwen in het succesvol afronden van mijn proefschrift heeft ervoor gezorgd dat ik 
zelf ook de energie bleef houden om door te gaan, bedankt! 
Dr. M.P.M.L. Snijders, beste Marc, wie had ooit gedacht dat het idee wat jij kreeg in 2010 zou 
uitmonden in dit proefschrift én in een groot landelijk RCT wat nog gaat volgen? Het heeft veel 
tijd en moeite gekost en we zijn veel obstakels tegengekomen, maar eindelijk is dit proefschrift 
dan toch afgerond. Continue heb je mij gestimuleerd om verder te gaan en om dit onder- 
zoek tot een goed einde te brengen. Zelfs tijdens jouw vakantie op het strand bleef je, 
bijna dagelijks, zeer kritisch stukken corrigeren. Hartelijk dank voor jouw inzet en enthousiasme, 
ik hoop in de toekomst ook nog veel van jouw klinische werk te kunnen leren!
Dr. S.F.P.J. Coppus, beste Sjors, we hebben jou iets later bij ons onderzoek betrokken en 
ook al paste dit niet helemaal binnen jouw aandachtsgebied, je was enorm enthousiast. 
Dit leidde al snel tot twee mooie publicaties. Hoewel je de laatste periode vaak tot over je 
oren in het werk zat, bleef je altijd meedenken als ik met vragen of geschreven teksten bij 
je aanklopte. Bedankt voor jouw snelle reactietijd en vermogen om op korte termijn 
knopen door te hakken, daardoor hebben we de deadline kunnen halen!
De leden van de promotiecommissie, prof. dr. J. van der Velden, prof. dr. M. Goddijn en 
dr. F.M. van Dunné, wil ik hartelijk danken voor het kritisch doornemen en beoordelen van 
mijn manuscript.
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Beste Roel de Heus, dank voor jouw input bij het uitvoeren van de retrospectieve studie 
in het RUMC. En wat hebben we zitten zweten op onze ZonMw aanvragen! Helaas zonder 
succes, maar dat heeft ons (jij weliswaar met een ander onderwerp op een andere locatie) 
er niet van weerhouden om door te gaan met het verrichten van onderzoek. 
Oud-collega’s van het Medisch Centrum Alkmaar, dank voor de samenwerking en 
begeleiding tijdens mijn eerste jaar als ANIOS. Het was een fijne kliniek waar ik mij al snel 
thuis voelde, dit zorgde ervoor dat ik veel van jullie heb kunnen leren.
Beste (oud-)gynaecologen van het CWZ: dr. van Bijsterveldt, dr. Bos, dr. Ebisch, dr. Franssen, 
dr. van Heteren, dr. de Kruif, dr. Nolens, dr. Schippers, dr. Snijders, dr. Sporken en dr. Stoutjesdijk. 
Ik ben jullie dankbaar voor alle steun en aanmoedigingen toen ik, na twee niet-succesvolle 
sollicitatierondes voor de opleiding, besloot om via een promotie-traject dit doel alsnog 
te bereiken. Ik heb ontzettend veel van jullie mogen leren in de kliniek, maar kreeg daarnaast 
ook de ruimte om aan mijn onderzoek te werken. Na mijn eerste ervaring in Alkmaar had 
ik niet verwacht nogmaals in zo’n fijn team te mogen werken!
Lieve verloskundigen, verpleegkundigen en doktersassistenten van het CWZ (sorry, dat 
zijn echt te veel namen om op te noemen!), dank voor jullie onvoorwaardelijke support! 
Hoe vaak jullie wel niet geroepen hebben dat ik echt in opleiding moest komen… dat 
heeft mij ontzettend geholpen om deze weg vol te houden. Dank voor alle goede 
gesprekken en steun in moeilijke tijden, maar ook voor de hilarische momenten en niet te 
stoppen lachbuien vooral zo aan het einde van de nachtdienst. En houd het afdelingsfeest 
erin, dat zijn bijzonder leuke onvergetelijke feestjes! 
Alle (oud-)arts-assistenten van het CWZ, bedankt voor jullie samenwerking en gezelligheid! 
Ik ben vooral de laatste groep, “de Gezanten van Snijders” (Bart, Caroline, Janneke, Linda, 
Lobke, Lotte, Martje, Roosmarie, Suzan en Veerle), enorm dankbaar dat ik het laatste half 
jaar zoveel vrije dagen (én “schrijfverlof” in de zomervakantie) heb kunnen opnemen om 
mijn promotie af te ronden. Lotte, ik ben heel blij dat jij het stokje van mij hebt over- 
genomen en “de grote trial” gaat uitvoeren! Ellen en Marjolein, bedankt voor jullie 
gezelligheid en luisterend oor tijdens de vele etentjes. Ellen, ook jij hebt dezelfde lange 
weg bewandeld. Elke keer als ik begon te twijfelen dacht ik aan jouw positieve instelling 
en het feit dat je hebt laten zien dat je deze weg met succes kunt afleggen. Marjolein, 
we begonnen tegelijk in het CWZ, jij als AIOS en ik als ANIOS. Inmiddels werk je elders 
als gynaecoloog, maar misschien kan ik in de toekomst weer als collega van jouw bak- 
kunsten genieten? 
Beste geneeskunde-meiden, onze etentjes en borrels zijn altijd gezellig! Helaas niet meer 
zo vaak als voorheen door onze wisselende diensten en woonplaatsen, maar het is altijd 
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gezellig om jullie weer te zien en te spreken. Laten we de wijn snel koud zetten en weer 
een datum plannen!
Lieve vrienden en vriendinnen (sorry, wederom te veel namen om op te noemen!), dank 
voor alle support in de goede en slechte tijden van de afgelopen jaren. De geweldige 
verjaardagsfeesten, koninginne- en koningsdag boottochten, de gave feesten tot diep in 
de nacht, de kerstdiners, de jaarlijkse wintersport (hopelijk wordt de zeilvakantie ook een 
terugkerend fenomeen), de diverse etentjes, barbecues, borrels en de heerlijk burgerlijke 
spelletjesavonden hebben al deze jaren voor meer dan genoeg afleiding en ontspanning 
gezorgd! 
Lieve allerbeste vriendinnen, Daniëlle en Leonieke, ontzettend bedankt dat jullie er altijd 
voor mij zijn! Ondanks jullie eigen drukke werk, wisselende diensten en moeilijke tijden, 
is er altijd ruimte om mijn ei kwijt te kunnen. Daniëlle, wat zal men blij zijn met jou als 
huisarts: altijd een luisterend oor, altijd willen weten hoe het nu écht met je gaat en na 
een gesprek met jou verschijnt er altijd weer een glimlach op je gezicht. Leonieke, ik ken 
weinig mensen die hun werk met zoveel passie en gedrevenheid uitvoeren als jij. Ook al 
ben je druk, je pakt alles aan en gaat door tot het doel bereikt is. Daarnaast krijg je het ook 
voor elkaar om alle contacten met familie en vrienden te onderhouden, ik ben trots op je! 
Meiden, ik ben blij met jullie vriendschap en geniet van de gezelligheid, en laten we vooral 
de ontspannende sauna-dagjes erin houden! 
Lieve familie, dank voor jullie steun in de afgelopen jaren. Hoewel jullie misschien niet 
altijd goed begrepen hoe het in elkaar steekt met de opleiding en waar ik nu inhoudelijk 
mee bezig was (of misschien heb ik het zelf onvoldoende uitgelegd?) jullie bleven altijd 
enthousiast en geïnteresseerd. Dank voor jullie aanmoedigingen en succes met het begrijpen 
van mijn boekje! Lieve oma, wat ben jij altijd trots geweest op “jouw eigen dokter”. Helaas ben 
je dat nu vaak weer vergeten, maar elk nadeel heeft zijn voordeel: hoe vaak ik het ook zal 
vertellen, jij reageert altijd weer even enthousiast! 
Lieve Klaas en Ilona, ontzettend bedankt voor jullie steun en aanmoedigingen, maar ook 
voor alle praktische hulp bij brandende autolampjes, achterstallig schoonmaakwerk in 
huis en tijdens het jaarlijkse oliebollen-bak-festijn! Bedankt dat jullie altijd voor ons klaar 
staan! 
Lieve mama en papa, dankzij jullie steun en aanmoedigingen ben ik zo ver gekomen en 
is het mij gelukt om dit doel te bereiken. Lieve mama, ik ben enorm trots op hoe jij je 
de afgelopen jaren staande hebt gehouden, ons hebt ondersteund, en nu zelf ook weer 
kunt genieten van het leven. We beseffen des te meer dat we moeten genieten van 
vandaag, en niets moeten uitstellen tot morgen. Lieve papa, hoe trots was jij toen ik 
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vertelde over dit onderzoek. Je sprak je gevoel niet altijd uit, maar ik zag het aan je. Het is 
een zware tijd geweest, maar eindelijk kan ik jou vertellen dat het is gelukt en ik weet hoe 
trots je daarop bent!
Lieve Roy, soms was ik best jaloers op jouw promotieonderzoek: direct starten na je 
master opleiding en er fulltime én betaald aan kunnen werken. Maar dat betekende natuurlijk 
niet dat het je gemakkelijk afging. Ik hoop dat we nog vele jaren samen op vakantie 
kunnen gaan, ik heb jou namelijk als voorbeeld nodig bij het skiën en wil ook het zeilen 
van je leren. Nynke, veel succes met de tweede helft van jouw promotieonderzoek en 
heel veel geluk samen met Roy!
Lieve Marco, hoe kan ik jou ooit genoeg bedanken voor alle steun, motiverende woorden 
en voor het begrip als ik weer eens in onze vrije tijd aan het werk ging. Jij stak veel tijd en 
energie in het realiseren van een site om mijzelf en mijn onderzoeksresultaten aan iedereen 
te presenteren: joycevandenberg.doctor. Maar ook de (verjaardag)feestjes die je altijd top 
wist te regelen, de vakanties en de heerlijke bank-hang-weekenden waarin we gemakkelijk 
een heel serie-seizoen wegkeken, maakten dat ik weer genoeg energie had om aan het 
werk te gaan. Mede dankzij jou had ik zoveel doorzettingsvermogen om mijn droom te 
bereiken, ik hou van je!
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Curriculum Vitae
Joyce van den Berg werd geboren op 27 oktober 1984 te Nijkerk waar zij samen met haar 
jongere broer Roy is opgegroeid. In 2002 behaalde zij haar vwo-diploma (profiel Natuur & 
Gezondheid met Latijn) aan ’t Hooghe Landt College te Amersfoort waarna zij startte 
met de studie Geneeskunde aan de Vrije Universiteit te Amsterdam. Van begin af aan is er 
interesse geweest in de gynaecologie, echter wekte ook de neurologie haar interesse wat 
ertoe leidde dat zij het profiel Neurowetenschappen met goed gevolg afrondde. Tijdens 
de co-schappen bleek haar hart bij de obstetrie en gynaecologie te liggen, en het oudste 
co-schap werd met goed succes op deze afdeling afgerond (Kennemer Gasthuis, Haarlem). 
Het keuze co-schap volgde zij bij een eerstelijns verloskundigen praktijk (Laan van de 
Helende Meesters, Amstelveen) waar nog meer ervaring met verloskunde werd opgedaan. 
Na afronding van de studie Geneeskunde eind 2008 begon zij begin 2009 als ANIOS 
Obstetrie & Gynaecologie in het Medisch Centrum Alkmaar (opleider dr. A.H. Adriaanse). 
Medio 2010 begon zij als ANIOS Obstetrie en Gynaecologie in het Canisius-Wilhelmina 
Ziekenhuis te Nijmegen (opleiders dr. J.M.J. Sporken en dr. M.P.L.M. Snijders). Alhier begon 
zij naast haar klinische taken als ANIOS dit promotieonderzoek in samenwerking met het 
Radboud Universitair Medisch Centrum te Nijmegen. Na afronding van het promotie-
traject zal zij starten met de opleiding tot gynaecoloog. Tijdens de studie en ANIOS-tijd in 
Alkmaar woonde Joyce van den Berg in Amsterdam, daarna is zij is terugverhuisd naar 
haar geboortestad Nijkerk waar zij samenwoont met Marco Schuurman. Samen maakten 
ze de website: joycevandenberg.doctor.
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